


Impact factor scientific publications Prof. Vaira

(Journal of Citation Reports® 2025)



C Index 22743

H Index 73



Curriculum Vitae Europass



Personal information

First name(s) / Surname(s) **Berardino Vaira**

Personal Address 7, via Zaccherini Alvisi, 40137, Bologna, Italy

Work Address Department of Internal Medicine
and Gastroenterology
S.Orsola Hospital, University of
Bologna
9, via Massarenti, 40100,
Bologna, Italy

Telephone(s) (39) 51/ 6364143-40 Mobile +39 348 23 40 319

Fax(es) +39 05139 87 94

E-mail berardino.vaira@unibo.it

Nationality Italian

Date of birth 07/12/1955

Gender Male

Tax code VRABRD55T07D643O

Occupational field **Full Professor in Internal Medicine**

Work experience

Dates From September 2004

Occupation or position held Editorial Board of Digestive & Liver Disease and The American Journal
of Gastroenterology

Main activities and responsibilities

Name and address of employer

Dates November 2004

Occupation or position held Editorial Board of World Journal of Gastroenterology

Main activities and responsibilities

Name and address of employer

Dates January 2003

Occupation or position held Editorial Board of Alimentary Pharmacology & Therapeutics

Name and address of employer

<p>Dates Occupation or position held Main activities and responsibilities Name and address of employer</p>	<p>March 1997 Editorial Board of Digestive Diseases and Sciences.</p>
<p>Honors and Awards</p>	<p>Menegatti M, Vaira D, Miglioli M, Holton J, Oderda G, Azzarone P, Gatto M, Landi F, Massardi B, Mulè P, Ricci C, Vergura M, Barbara L. Serum Pepsinogen I and gastrin levels in Helicobacter pylori IgG seropositive asymptomatic blood donors. <u>Best oral presentation; Berlin 1995</u></p> <p>Vaira D, Miglioli M, Menegatti M, Holton J, Biasco G, Mulè P, Boschi S, Bisceglia G, Lombardi M, Vergura M, Azzarone P, Serra C, Conte R, Barbara L. Endoscopic findings in 288 asymptomatic blood donors according to high levels of IgG to Helicobacter pylori. <u>Best oral presentation; Barcelona 1993.</u></p> <p>D'Anastasio C, Vaira D, Holton J, Dowsett JF, Bertone F, Poli AN, Maldini R, Salmon PR, Gandolfi L. Detection of Campylobacter pylori (CP) associated gastritis in abattoir workers by Elisa Technique and endoscopy. Is a zoonosis? <u>Best oral presentation. Roma September 1988.</u></p>

Education and training

Dates	2021
Title of qualification awarded	Director of the School of specialization in "Medicina D'Urgenza e Dell'Emergenza" (D.I. 68/2015)
Name and type of organisation providing education and training	Department of Internal Medicine & Gastroenterology at the University of Bologna, Italy
Dates	2011
Title of qualification awarded	Full Professor in Internal Medicine
Name and type of organisation providing education and training	Department of Internal Medicine & Gastroenterology at the University of Bologna, Italy
Dates	2000
Title of qualification awarded	Associate Professor in Internal Medicine
Name and type of organisation providing education and training	Department of Internal Medicine & Gastroenterology at the University of Bologna, Italy
Dates	1991-2000
Title of qualification awarded	Lecturer; Department of Internal Medicine & Gastroenterology
Name and type of organisation providing education and training	University of Bologna, Italy
Dates	1987-1990
Title of qualification awarded	Post Graduate Clinical Assistant
Name and type of organisation providing education and training	Department of Gastroenterology, The Middlesex Hospital, London, UK
Level in national or international classification	Graduated
Dates	1988
Title of qualification awarded	Post Graduate School of Internal Medicine
Name and type of organisation providing education and training	Medical School of the University of Bologna, Italy
Level in national or international classification	Graduated with 70/70
Dates	1984
Title of qualification awarded	Post Graduate School of Gastroenterology & Endoscopy
Name and type of organisation providing education and training	Medical School of the University of Chieti, Italy

Level in national or international classification | Graduated with 70/70 cum laude

Dates | 1980

Title of qualification awarded | MD at the Medical School of the University of Bologna, Italy

Name and type of organisation providing education and training | University of Bologna, Italy

Level in national or international classification | Graduated with full mark 110/110

Personal skills and competences

Mother tongue(s) | **Italian**

Other language(s) | **English**

Self-assessment
European level (*)

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
C2	C2	C2	C2	C2

English

(*) [Common European Framework of Reference for Languages](#)

Technical skills and competences | Endoscopy: diagnostic and therapeutic upper and lower GI tract

Organizations of International Scientific Meetings:

- Advanced ERCP course "The Middlesex Hospital" University of London, 1987.
- Advanced ERCP course "The Middlesex Hospital" University of London, 1988.
- Advanced ERCP course "The Middlesex Hospital" University of London, 1989.
- Interdisciplinary Course in Gastroenterology "Helicobacter Pylori Infection": Geneva 1993.
- Educational Training Workshop in Helicobacter Pylori: Bologna 1994.
- II Educational Training Workshop in Helicobacter Pylori: Bologna 1995.
- III Educational Training Workshop in Helicobacter Pylori: Bologna 1996.
- IV Educational Training Workshop in Helicobacter Pylori: Bologna 1997.
- V Educational Training Workshop in Helicobacter Pylori: Bologna 1998
- VI Educational Training Workshop in Helicobacter Pylori: Bologna 1999
- VII Educational Training Workshop in Helicobacter Pylori: Bologna 2000
- VIII Educational Training Workshop in Upper and Lower GI Diseases: Bologna 2001
- IX Educational Training Workshop in Digestive Diseases: Bologna 2002
- X Educational Training Workshop in Digestive and Liver Diseases: Bologna 2003
- XI Educational Training Workshop in Digestive and Liver Diseases: Bologna 2004

Patent:

On April 13th 2007: International Patent Application PCT/IT 2007/000270 on;
METHOD FOR DETERMINING HELICOBACTER PYLORI CHEMOSENSITIVITY

Computer skills and competences | Microsoft Office (Word, Powerpoint)

Scientific publications

1982

1. Corazza G R, Risoni M, Milletti S, **Vaira D**, Gasbarrini G.
Mechanism of thrombocytosis in Whipple's disease.
Gastroenterology 1982; 82: 165 (letter) (I.F. 25.9).

1983

2. Corazza G R, Frisoni M, **Vaira D**, Gasbarrini G.
Effect of gluten-free diet on splenic hypo function of adult celiac disease.
Gut 1983; 24: 228-230 (I.F. 26.2).
3. Corazza G R, Frisoni M, **Vaira D**, Gasbarrini G.
Splenic function in adult celiac disease.
Gut 1983; 82: 964-965 (letter) (I.F. 26.2).
4. Corazza G R, **Vaira D**, Milletti S, Vanzini S, Gasbarrini G.
Controlled clinical evaluation of Pinaverium Bromide and Trimebutine in functional disorders of the colon.
Acta Therapeutica 1983; 9: 383-389.

1984

5. Corazza G R, Tarozzi C, **Vaira D**, Frisoni M, Gasbarrini G.
Return of splenic function after splenectomy: how much tissue is needed?
British Medical Journal 1984; 289: 861-864 (I.F. 43).
6. Corazza G R, Frisoni M, **Vaira D**, Gasbarrini G.
Fatal pneumonia in a patient with celiac disease and splenic atrophy.
The Italian Journal of Gastroenterology 1984; 16: 300-301 .
7. Gasbarrini G, Corazza G R, **Vaira D**, Frazzoni M, Strocchi A, Prati C, Feliciani M, Frisoni M.
Critical evaluation of malabsorption test.
Problems and controversies in Gastroenterology 1984; 123-130.

1986

8. Gandolfi L, Rossi A, **Vaira D**, Tonti R, Ramini R.
Endoscopic retrograde cholangiopancreatography (ERCP) in the elderly.
Acta Gastro-Enterologica Belgica 1986; II 602-607.

1988

9. **Vaira D**, Holton J, Londei M, Beltrandi E, Salmon P. R, D'Anastasio C, Dowsett J, Bertoni F, Grauenfels P, Gandolfi L.
Campylobacter pylori in abattoir workers: is it a zoonosis?
The Lancet: 1988; ii 725-726 (I.F. 88.5).
10. **Vaira D**, D'Anastasio C, Holton J, Dowsett J, Londei M, Salmon P R, Gandolfi L.
Is Campylobacter pylori a zoonosis?
The Lancet 1988; ii: 1149 (letter) (I.F. 88.5).
11. **Vaira D**, Holton J, Cairns S. R., Falzon M, Polydorou A, Dowsett J, Salmon P R.
Antibody titres to Campylobacter pylori after treatment for gastritis.
British Medical Journal 1988: 297: 397 (I.F. 43)

12. Dowsett J, **Vaira D**, Polydorou A, Russel R C G, Salmon P R.
Interventional endoscopy in the pancreatobiliary tree
The American Journal of Gastroenterology 1988; 83: 1328-1336 **(I.F. 10.9)**.
13. Gandolfi L, **Vaira D**, Bertoni F, Rossi A, Solmi L, Leo P, Muratori R.
Cancer of gastric stump in Italy, 1979-1986.
Gastrointestinal Endoscopy 1988; 34: 242-246 **(I.F. 7.5)**.
14. **Vaira D**, Holton J, Falzon M, Cairns S, Dowsett J, Polydorou A, Salmon P R.
Investigation of Campylobacter pylori associated gastritis by histology, culture, urease test, brushings and antibody levels.
The Italian Journal of Gastroenterology 1988: 20: 299-304 .
15. **Vaira D**, Holton J Cairns S, Polydorou A, Falzon M, Dowsett J, Salmon P R.
Urease test for Campylobacter pylori: care in interpretation.
Journal of Clinical Pathology 1988; 41: 812-13. **(I.F. 5)**.
16. **Vaira D**, Holton J, Cairns S, Falzon M, Salmon P R.
Four hour rapid urease test (RUT) for detecting Campylobacter pylori: is it reliable enough to start treatment?
Journal of Clinical Pathology 1988; 41: 355-356 (letter) **(I.F. 5)**.
17. Dowsett J, Miller R, Davidson R, **Vaira D**, Polydorou A, Cairns S R, Weller I V D.
Sclerosing Cholangitis in Acquired Immunodeficiency Syndrome.
Scandinavian Journal of Gastroenterology 1988; 23: 1267-1274 **(I.F. 1.7)**.

1989

18. **Vaira D**, D'Anna L, Ainley C, Dowsett J, Williams S, Baillie J, Cairns S, Croker J, Salmon P, Cotton P, Russell C, Hatfield A.
Endoscopic sphincterotomy in 1000 consecutive patients.
Lancet 1989; ii: 431-434 **(I.F. 88.5)**.
19. Oderda G, **Vaira D**, Holton J, Ainley C, Altare F, Ansaldi N.
Amoxicillin plus tinidazole for Campylobacter pylori gastritis in children: assessment by serum IgG antibody, pepsinogen I, and gastrin levels.
Lancet 1989; i: 690-692. **(I.F. 88.5)**.
20. Smith T, **Vaira D**, Ailey C, Holton J.
Campylobacter pylori, gastrin and duodenal ulcer.
Lancet 1989; ii: 431-434 (letter) **(I.F. 88.5)**.
21. **Vaira D**, Holton J, Osborn J, Dowsett J, McNeil I, Hatfield A.
Use of endoscopy in patients with dyspepsia
British Medical Journal 1989; 299: 237 **(I.F. 43)**.
22. **Vaira D**, Holton J, McNeil N I.
Use of endoscopy in patients with dyspepsia
British Medical Journal 1989; 299: 621-622 (letter) **(I.F. 43)**.
23. Dowsett J, **Vaira D**, Hatfield A R W, Cairns S R, Polydorou A, Frost R, Croker J, Cotton P B, Russell R C. G, Mason R R.
Endoscopic biliary therapy using the combined percutaneous and endoscopic technique.
Gastroenterology 1989; 96: 1180-6. **(I.F. 25.9)**.

24. **Vaira D**, Holton J.
Serum immunoglobulin G antibody levels for Campylobacter pylori diagnosis.
Gastroenterology 1989; 97: 1069-1070 (letter) (I.F. 25.9).
25. **Vaira D**, Dowsett J, Hatfield A R W, Cairns S R, Polydorou A, Cotton P B, Salmon P R, Russell R C G.
Is duodenal diverticulum a risk factor for sphincterotomy?
Gut 1989; 30: 939-942 (I.F. 26.2).
26. Oderda G, **Vaira D**, Holton J, Dowsett J, Ansaldi N.
Serum pepsinogen I and IgG antibody to Campylobacter pylori in non-specific abdominal pain in childhood.
Gut 1989; 30:912-916. (I.F. 26.2).
27. **Vaira D**, Oderda G, Holton J, Smith A, Ainley C.
¹⁴C-Urea Test for C. pylori.
Gut 1989; 30:1657 (letter) (I.F. 26.2).
28. **Vaira D**, Holton J.
Urease test for Campylobacter pylori detection.
The American Journal of Gastroenterology 1989; 84: 836-837 (letter) (I.F. 10.9).
29. Polydorou A, Dowsett J, **Vaira D**, Salmon P R, Cotton P B, Russell R C G.
Endoscopic therapy of the sump syndrome.
Endoscopy 1989; 21, 126-130. (I.F. 10.9).
30. . Dowsett J, Cairns S R, **Vaira D**, Polydorou A, Hatfield A R W, Russell R C G.
Endoscopic endoprosthesis insertion following failure of cholecystojejunostomy in pancreatic carcinoma.
British Journal of Surgery 1989; 76: 454-456 (I.F. 8.7).
- 31 **Vaira D**, Holton J, Ainley C, Salmon P.
Campylobacter pylori and gastritis.
Current Opinion in Gastroenterology 1989; 5: 817-823 (I.F. 2.5).
32. **Vaira D**, Holton J, Salmon P R.
How specific is the rapid urease test for diagnosing Campylobacter pylori?
Journal of Clinical Pathology 1989; 42: 671 (letter) (I.F. 2).
33. **Vaira D**, Holton J, Ainley C, Londei M, Romanos A, Maldini M, Gandolfi L.
The source of Campylobacter pylori.
Biomed and Pharmacotherapeutics 1989; 43: 447-450 (I.F. 7.5).

1990

34. Bedwell J, Holton J, **Vaira D**, Mac Robert A, Bown S.
In vitro killing of Helicobacter pylori with photodynamic therapy.
Lancet 1990; i: 1287 (letter) (I.F. 88.5).
35. Corazza G R, Menozzi M, Strocchi A, Rasciti R, **Vaira D**, Lecchini R, Avanzini P, Chezzi C, Gasbarrini G.
The diagnosis of small bacterial overgrowth.
Gastroenterology 1990; 98: 302-309 (I.F. 25.9).
36. Dowsett J, Polydorou A, **Vaira D**, D'Anna L, Ashraf M, Croker J, Salmon P, Russell R, Hatfield A.
Needle knife papillotomy: how safe and how effective?
Gut 1990; 31: 905-908 (I.F. 26.2).

37. **Vaira D**, Holton J, Osborn J, D'Anna L, Romanos A, Falzon M, McNeil N I. Endoscopy in dyspeptic patients: Is gastric mucosal biopsy useful? The American Journal of Gastroenterology 1990; 85:701-704 (I.F. 10.9).
38. **Vaira D**, Holton J, Ainley C, Barbara L. Helicobacter pylori and acid-related diseases of the stomach: mechanisms of pathogenesis. Current Opinion in Gastroenterology 1990; 6: 882-887 (I.F. 2.5).
39. Oderda G, **Vaira D**, Dell' Olio D, Holton J, Forni M, Altare F, Ansaldi N. Serum pepsinogen I and gastrin concentrations in children positive for Helicobacter pylori. Journal of Clinical Pathology 1990; 43: 762-765 (I.F. 2).
40. **Vaira D**, Holton J, Dowsett J, Oderda G, Barbara L. Helicobacter pylori: its role in gastric disease. Digestive Disease 1990; 8:322-336 (I.F. 2.1).
41. **Vaira D**, Holton J, Oderda G, Taylor D, Colecchia A, Gandolfi L. Transmission and source of Helicobacter pylori in Menge H, Gregor M, Tytgat G, Marshall B, McNulty C. Helicobacter pylori: epidemiology and diagnosis. Insights into Helicobacter pylori and peptic disorders 1990; 11: 104-109.

1991

42. **Vaira D**, Miglioli M, Holton J, Mulè P, Barbara L. Screening for Helicobacter pylori. Lancet 1991, ii: 1149 (letter) (I.F. 88.5).
43. Nussinson E, Cairns S, **Vaira D**, Dowsett J, Mason R. A 10 year single centre experience of percutaneous and endoscopic extraction of bile duct stones with T tube in situ. Gut 1991; 32: 1040-1043 (I.F. 26.2)
44. **Vaira D**, Holton J. Is gastric mucosal biopsy useful? The American Journal of Gastroenterology 1991; 96: 647-48 (letter) (I.F. 10.9).
45. **Vaira D**, Holton J, Miglioli M, Barbara L. Pathogenic mechanism of acid-related diseases: Helicobacter and other spiral organisms. Current Opinion in Gastroenterology 1991; 7: 881-887 (I.F. 2.5).
46. **Vaira D**, Modugno V, Miglioli M, Holton J, Vergura M, Marchesini F, Scagliusi V, Barbara L. Prevalence of Helicobacter pylori in military barracks. The Italian Journal of Gastroenterology 1991; 25: 215 .
47. Oderda G, **Vaira D**, Holton J, Ainley C, Altare F, Boero M, Smith A, Ansaldi N. Helicobacter pylori in children with peptic ulcer and their families. Digestive Diseases and Sciences 1991; 36: 572-576 (I.F. 2.9).
48. Oderda G, **Vaira D**. Infection à Helicobacter pylori dans l'enfance. Acta Endoscopica 1991; 21: 43-47 (I.F. 0.2).
49. **Vaira D**, Holton J, Barbara L. Helicobacter pylori and Gastroduodenal diseases. Gastroenterology International 1991; 4: 70-76

1992

50. Oderda G, **Vaira D**, Holton J.
Age-related increase of Helicobacter pylori frequency in symptom-free and dyspeptic children.
Lancet 1992; ii: 671-672 (letter) (I.F. 88.5).
51. Oderda G, **Vaira D**, Ainley C, Holton J, Osborn J, Altare F, Ansaldi N.
Eighteen month follow up of Helicobacter pylori positive treated with amoxicillin and tinidazole.
Gut 1992; 33: 1328-30 (I.F. 26.2).
52. **Vaira D**, Holton J, Miglioli M, Mulè P, Menegatti M, Barbara L.
Helicobacter pylori and other spiral organisms.
Current Opinion in Gastroenterology, 1992; 8: 918-926 (I.F. 2.5).
53. **Vaira D**, Ferron P, Negrini R, Cavazzini L, Holton J, Ainley C, Londei M, Vergura M, Dei R, Colecchia A, Taylor D, Pieracci F, Nenci I, Gandolfi L, Barbara L.
Detection of Helicobacter pylori-like organisms in the stomach of some food-source animals using a monoclonal antibody.
The Italian Journal of Gastroenterology 1992; 24:181-184 .
54. **Vaira D**, Holton J, Ainley C, Falzon M, Osborn J, D'Anna L, Romanos A, Chandrakumaran K, McNeil N I.
Double blind trial of colloidal bismuth subcitrate versus placebo in Helicobacter pylori positive patients with non-ulcer dyspepsia.
The Italian Journal of Gastroenterology 1992; 24: 400-404 .
55. Croker JR, Williams SG, Charlton M, **Vaira D**, Dowsett J.
Endoscopic therapy for bile duct stones in a geriatric population.
Postgraduate Medical Journal 1992; 68: 457-60 (I.F. 2.5).
56. Ahmed A, Holton J, **Vaira D**, Smith SK, Hoult JRS.
Eicosanoids synthesis and Helicobacter pylori associated gastritis: increase in leukotriene C4 generation associated with H. pylori colonisation.
Prostaglandins 1992; 44: 75-86.

1993

57. **Vaira D**, Menegatti M, Miglioli M, Barbara L.
Source of Helicobacter pylori infection.
The American Journal of Gastroenterology 1993; 88: 1297 (letter) (I.F. 10.9).
58. **Vaira D**, Corbelli C, Brunetti G, Menegatti M, Levorato M, Mulè P, Colombo P, Miglioli M, Barbara L.
Gastric retention of sucralfate gel and suspension in upper gastrointestinal disease.
Alimentary Pharmacology & Therapeutic 1993; 7: 531-535 (I.F.7.4).
59. Biasco G, Paganelli GM, **Vaira D**, Holton J, Di Febo G, Brillanti S, Miglioli M.
Serum pepsinogen I and II concentrations and IgG antibody to Helicobacter pylori in dyspeptic patients.
Journal of Clinical Pathology 1993; 46: 826-828 (I.F. 2).
60. **Vaira D**, Miglioli M, Menegatti M, Mulè P, Barbara L.
Treatment of symptom-free Helicobacter pylori-positive subjects.
European Journal of Gastroenterology & Hepatology 1993; 5: 96-98 (I.F. 1.8).
61. Mulè P, **Vaira D**, Menegatti M, Boschi S, Miglioli M, Barbara L.
Clinical aspects of serology in the diagnosis of Helicobacter pylori infection.
European Journal of Gastroenterology & Hepatology 1993; 5: 54-56 (I.F. 1.8).
62. Menegatti M, **Vaira D**, Mulè P, Miglioli M, Barbara L.
Comparison of urease tests for the diagnosis of Helicobacter pylori infection.
European Journal of Gastroenterology & Hepatology 1993; 5: 38-40 (I.F.2.6).
63. **Vaira D**, Cairns S, Miglioli M, Mulè P, Menegatti M, Barbara L.

64. **Vaira D**, Miglioli M, Mulè P, Holton J, Menegatti M, Vergura M, Biasco G, Conte R, Logan R, Barbara L.
Prevalence of peptic ulcer in Helicobacter pylori positive blood donors.
Gut 1994; 35: 309-312 (I.F. 26.2)
65. Chandrakuramaran K, **Vaira D**, Hobsley M.
Duodenal ulcer, Helicobacter pylori, and gastric secretion.
Gut 1994; 35: 1033-1036 (I.F. 26.2)
66. Gionchetti P, **Vaira D**, Campieri M, Holton J, Menegatti M, Belluzzi A, Bertinelli E, Ferretti M, Brignola C, Miglioli M, Barbara L.
Enhanced mucosal interleukin 6 and 8 in Helicobacter pylori positive dyspeptic patients.
The American Journal of Gastroenterology 1994; 88.5: 883-887 (I.F. 10.9).
67. **Vaira D**, Holton J, Miglioli M, Menegatti M, Mulè P, Barbara L.
Peptic ulcer disease and Helicobacter pylori infection.
Current Opinion in Gastroenterology 1994; 10: 98-104 (I.F. 2.5).
68. Oderda G, **Vaira D**, Holton J.
Seroconversion of Helicobacter pylori.
Journal of Clinical Pathology 1993; 47: 286 (letter) (I.F. 2).
69. **Vaira D**, Menegatti M, Miglioli M, Mosconi G, Mulè P, Barbara L.
Tetracycline for Helicobacter pylori.
Annals of Experimental and Clin Med 1994; 2: 90-94

1995

70. Menegatti M, **Vaira D**, Miglioli M, Vergura M, Holton J, Petronelli A, Biasco G, Gusmaroli R, Milesi F, Ricci C, Azzarone P, Maiolo P, Casadei A, Mulè P, Rodi M, Giorcelli W, Zambelli A, Lupinacci G, Pannuti F, Barbara L.
Helicobacter pylori in patients with gastric and non gastric cancer.
The American Journal of Gastroenterology 1995; 90: 1278-1281 (I.F.10.9).
71. Holton J, **Vaira D**, Menegatti M, Barbara L.
The suscepibility of Helicobacter pylori to the rifamycin, Rifaximin.
Journal of Antimicrobial Chemotherapy 1995; 35: 545-549 (I.F.5.8).
72. Biselli R, **Vaira D**, Miglioli M, Menegatti M, Nisini R, Barbara L, D'Amelio R.
Spectrotypic analysis of antibodies to Helicobacter pylori in patients with antral gastritis and duodenal ulcer.
Journal of Clinical Pathology 1995; 48:1117-21. (I.F. 2).
73. **Vaira D**, Miglioli M, Menegatti M, Holton J, Boschini A, Vergura M, Ricci C, Azzarone P, Mulè P, Barbara L, Ainley C.
Helicobacter pylori status, endoscopic findings, and serology in HIV-1-positive patients.
Digestive Disease and Sciences 1995; 40: 1622-1626. (I.F. 2.5).

1996

74. **Vaira D**, Stanghellini V, Menegatti M, Miglioli M, Corinaldesi R & The Italian Helicobacter Study Group.
IgG ELISA antibodies and detection of Helicobacter pylori in elderly patients.
Lancet 1996; i: 269-270 (letter) (I.F. 88.5).
75. Negrini R, Savio A, Poiesi C, Appelmek BJ, Buffoli F, Paterlini A, Cesari P, Graffeo M, **Vaira D**, Franzin G.
Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis.
Gastroenterology 1996; 111:655-65. (I.F. 25.9).
76. Biasco G, Paganelli GM, Terranova A, Santucci R, Renga M, **Vaira D**, Amorosi A, Pileri S.
Observer variation in histological assessment of Helicobacter pylori on gastric biopsies.
The American Journal of Gastroenterology 1996; 91: 1282 (letter) (I.F. 10.9).
77. Miglioli M, Bianchi Porro G, **Vaira D**, Menegatti M, Brunetti G, Petrillo M, Ardizzoni S, Frizziero L, Montrone F, Grandinetti G.
Prevention with sucralfate gel on NSAID-induced Gastroduodenal damage in arthritic patients.
The American Journal of Gastroenterology 1996; 91: 2367-71 (I.F. 10.9).
78. Menegatti M, **Vaira D**, Holton J, Miranda F, Ricci C, Gusmaroli R, Ainley C, Miglioli M, Barbara L.
Serological response to Helicobacter pylori in gastric and non gastric cancer.
Clinical Science 1996; 91:219-223. (I.F. 7.7).
79. **Vaira D**.
How to manage the dyspeptic patient.
Helicobacter 1996; 1: 261-62. (I.F. 4.3).

1997

80. **Vaira D**, Menegatti M, Miglioli M.
What is the role of *Helicobacter pylori* in complicated ulcer disease?
Gastroenterology 1997; 113: S78-84 (I.F. 25.9).
81. Palli D, **Vaira D**, Menegatti M, Saieva C & Italian *Helicobacter Pylori* Study Group
A serologic survey of *Helicobacter pylori* infection in 3281 patients endoscoped for upper gastrointestinal symptoms through Italy.
Alimentary Pharmacology & Therapeutics 1997; 11: 719-28 (I.F. 6.7)
82. **Vaira D**, Stanghellini V, Menegatti M, Miglioli M, Corinaldesi R & The Italian *Helicobacter Pylori* Study Group.
Prospective screening of dyspeptic patients by *Helicobacter pylori* serology: a worldwide safe policy?
Endoscopy 1997; 29: 595-601 (I.F. 12.8).
83. **Vaira D**, Menegatti M, Landi F, Ricci C, Ali' A, Miglioli M & The Italian *Helicobacter Pylori* Study Group.
Usefulness of serology in pre endoscopic screening.
Helicobacter 1997; 2: S38-43. (I.F. 4.3).
84. Oderda G, Ponzetto A, Boero M, Bellis D, Forni M, **Vaira D**, Ansaldi N.
Family treatment of symptomatic children with *Helicobacter pylori* infection.
The Italian Journal of Gastroenterology 1997; 29: 509-14 .
85. Siringo S, **Vaira D**, Menegatti M, Piscaglia F, Soccora S, Miglioli M, Corinaldesi R, Bolondi L
High prevalence of *Helicobacter pylori* in liver cirrhosis. Relationship with clinical and endoscopic features and the risk of peptic ulcer.
Digestive Disease and Sciences 1997; 42: 2024-30 (I.F. 2.5).
86. **Vaira D**, Menegatti M, Miglioli M, Ferrieri A, Holton J, Biasco G, Azzarone P, Ricci C, Gusmaroli R, Milesi F, Rodi M, Giorcelli W, Barbara L.
Rifaximin suspension for the eradication of *Helicobacter pylori*.
Current Therapeutic Research 1997; 58: 300-308 (I.F. 1.5).

1998

87. Figura N, Vindigni C, Covacci A, Presenti L, Burrone D, Vernillo R, Banducci T, Roviello F, Marrelli D, Biscontri M, Kristodhullu S, Gennari C, **Vaira D**.
CagA positive and negative *Helicobacter pylori* strains are simultaneously present in the stomach of most patients with non ulcer dyspepsia: relevance to histological damage.
Gut 1998; 42: 772-778 (I.F. 26.2)
88. **Vaira D**, Holton J, Menegatti M, Landi F, Ricci C, Ali' A, Gatta L, Farinelli S, Acciardi C, Massardi B, Miglioli M & The Italian *Helicobacter Pylori* Study Group.
Blood tests in management of *Helicobacter pylori* infection.
Gut 1998; 42: S39-S46 (I.F. 26.2)
- 88.5. Peitz U, Menegatti M, **Vaira D**, Malfertheiner P.
The European Meeting on *Helicobacter pylori*. Therapeutic news from Lisbon.
Gut 1998; 42: S66-S69 (I.F. 26.2)

90. Neri M, Vaira D, Palli D, Menegatti M, Landi F, Saieva C, Ricci C, Miglioli M & The Italian Helicobacter Pylori Study Group.
Symptoms and Helicobacter pylori, any link?
The American Journal of Gastroenterology 1996; 93: 2633-34 (letter) **(I.F. 10.9)**
91. **Vaira D**, Ali' A, Gatta L, O'Morain C.
Treatment of Helicobacter pylori
Current Opinion in Gastroenterology 1998; 14: S71-S78 **(I.F. 4.3)**.
92. **Vaira D**, Holton J.
H pylori and gastric physiology
Helicobacter 1998; 3: 2-3. **(I.F. 4.3)**.
93. **Vaira D**, Menegatti M, Salardi S, Ali A, Stella FA, Figura N, Landi F, Holton J, Farinelli S, Cuccaro V, Miglioli M, Cacciari E.
Helicobacter pylori and diminished growth in children: is it simply a marker of deprivation?
The Italian Journal of Gastroenterology 1998; 30: 129-33. .
94. **Vaira D**, Menegatti M, Gatta L, Ricci C, Landi F, Ali A, Miglioli M, Holton J.
Routes of transmission of Helicobacter pylori infection.
The Italian Journal of Gastroenterology 1998; 30 (Suppl. 3): S 279-85.
95. Ricci C, Gatta L, Miglioli M, **Vaira D**.
Therapeutic news on Helicobacter pylori from Budapest and Wien.
The Italian Journal of Gastroenterology 1998; 30: 129-33. .
96. Figura N, Cetta F, Angelico M, Montalto G, Cetta D, Pacenti L, Vindigni C, **Vaira D**, Festuccia F, De Santis A, Rattan G, Giannace R, Campagna S, Gennari C.
Most Helicobacter pylori infected patients have specific antibodies, and some also have H. Pylori antigens and genomic material in bile. Is it a risk factor for gallstone formation?
Digestive Disease and Sciences 1998; 43:854-862. **(I.F. 2.5)**.
97. Menegatti M, **Vaira D**, Figura N, Holton J, Biasco G, Ricci C, Oderda G, Conte R, Miglioli M.
Clinical significance of Helicobacter pylori seropositivity and seronegativity in asymptomatic blood donors.
Digestive Disease and Sciences 1998; 43: 2542-48. **(I.F. 2.5)**.
98. Holton J, Besset C, Youinou P, **Vaira D**.
Emerging therapeutic targets in the eradication of Helicobacter pylori.
Emerging Therapeutic Targets 1998; 2: 107-123.
- 1999**
99. **Vaira D**, Malfertheiner P, Megraud F, Axon ATR, Deltenre M, Hirschl A, Gasbarrini G, O' Morain C, Pajares JG, Quina M, Tytgat GNJ & European Helicobacter pylori HPSA study Group.
Diagnosis of Helicobacter pylori infection using a novel, non-invasive antigen based assay in a European multicentre study.
Lancet 1999; 354: 30-33 **(I.F. 88.5)**.
100. **Vaira D**, Malfertheiner P, Megraud F, Axon ATR, & European Helicobacter pylori HPSA Study Group.
Diagnosis of Helicobacter pylori infection by HpSA.
Lancet 1999; 354: 1732 (letter) **(I.F. 88.5)**.

101. **Vaira D**, Holton J, Menegatti M, Ricci C, Landi F, Ali' A, Gatta L, Acciardi C, Farinelli S, Crosatti M, Berardi S, Miglioli M.
New immunological-based assays for the diagnosis of Helicobacter pylori infection.
Gut 1999, 45: 1 23-27 (I.F. 26.2)
102. Ali' A, Menegatti M, Gatta L, Mucci F, Landi F, Holton J, Ricci C, Acciardi C, Miglioli M, **Vaira D**.
A second-line anti-helicobacter pylori therapy in patients with previously failed treatment.
The American Journal of Gastroenterology 1999; 94 (8): 2321-23 (letter) (I.F. 10.9).
103. van der Hulst RWM, Lamouliatte H, Megraud F, Pounder RE, Stolte M, **Vaira D**, Williams M, Tytgat GNJ. Laser assisted ratio analyser-¹³C-urea breath testing. A novel non-invasive system for the diagnosis of H pylori infection. A prospective comparative diagnostic multicentre study.
Alimentary Pharmacology & Therapeutics 1999; 13: 1171-1177 (I.F. 6.7).
104. Figura N, Perrone F, Gennari C, Orlandini G, Bianciardi L, Giannace R, Vagliasinti N. **Vaira D**, Rottoli P.
Food allergy and Helicobacter pylori infection.
The Italian Journal of Gastroenterology 1999; 31: 186-91. .
105. Salardi S, Cacciari E, Menegatti M, Landi F, Mazzanti L, Stella FA, Pirazzoli P, **Vaira D**.
Helicobacter pylori and Type 1 Diabetes Mellitus in Children.
Journal of Paediatric Gastroenterology & Nutrition 1999; 28-307-309 (I.F. 2.7).
106. Dore MP, Bilotta M, **Vaira D**, Manca A, Massarelli G, Gioacchini L, Atzei A, Pisanu G, Graham DY, Realdi G.
High prevalence of Helicobacter pylori infection in shepherds.
Digestive Disease and Sciences 1999; 44: 1161-64 (I.F. 2.5).
107. Fusconi M, **Vaira D**, Menegatti M, Farinelli S, Figura N, Holton J, Ricci C, Corinaldesi R, Miglioli M.
Anti-cagA reactivity in Helicobacter pylori negative subjects: a comparison of three different methods.
Digestive Disease and Sciences 1999; 44: 1691-1695 (I.F. 2.5).
108. Figura N, Di Cairano G, Lorè F, Guarino E, Gragnoli A, Cataldo D, Giannace R, **Vaira D**, Bianciardi L.
Kristodohullu S, Lenzi C, Torricelli V, Orlandini G, Gennari C.
The infection by Helicobacter pylori strains expressing CagA is highly prevalent in women with autoimmune thyroid disorders.
Journal of Physiology and Pharmacology 1999; 50: 817-26 (I. F. 1.7).
109. Cacciari E, Menegatti M, Salardi S, Ali' A, Stella FA, Figura N, Landi F, Holton J, Farinelli S, Cuccaro V, Miglioli M, **Vaira D**.
Helicobacter pylori infection and cytotoxic antigen associated gen "A" status in short children.
Journal of Paediatric Endocrinology & Metabolism 1999; 12-197-201 (I.F.1).

110. Barnes I, Holton J, **Vaira D**, Spigelman M, Thomas MG
An assessment of the long-term preservation of the DNA of a bacterial pathogen in ethanol-preserved archival material.
Journal of Pathology 2000; 192: 554-9 (I.F. 5.2).
111. **Vaira D**, Malfertheiner P, Mégraud F, Axon ATR, Deltenre M, Gasbarrini G, O' Morain C, Pajares JG, Quina M, Tytgat GNJ & European Helicobacter pylori HPSA study Group.
Non invasive antigen based assay for assessing Helicobacter pylori eradication. A European multicentre study.
American Journal of Gastroenterology 2000; 95: 925-929. (I.F. 10.9)
112. Menegatti M, **Vaira D**, Figura N, Palli D, Miglioli M & The Italian Helicobacter pylori Study Group
Age, Helicobacter pylori and/or CagA antibodies as a pre-endoscopic screening policy.
American Journal of Gastroenterology 2000; 95: 320-21. (letter) (I.F. 10.9)
113. Checchi L, Felice P, Acciardi C, Ricci C, Gatta L, Polacci R, Holton J, **Vaira D**.
Absence of Helicobacter pylori in dental plaque assessed by stool test.
American Journal of Gastroenterology 2000, 95: 3005-6 (letter) (I.F.10.9)
114. **Vaira D**, Holton J, Menegatti M, Ricci C, Gatta L, Geminiani A, Miglioli M.
Review article: invasive and non-invasive tests for Helicobacter pylori diagnosis.
Alimentary Pharmacology & Therapeutics 2000; 14: 13-22 (I.F. 6.7).
115. **Vaira D**, Ricci C, Perna F, Gatta L, Tampieri A, Miglioli M
Diagnosis of Helicobacter pylori infection: which is the best test? Stool test
Digestive Liver Diseases 2000; 32: S193-S195 (I.F. 3.5).
116. **Vaira D**, Menegatti M, Ricci C, Gatta L, Berardi S, Miglioli M
Accurate diagnosis of Helicobacter pylori: stool tests
Gastroenterology Clinics of North America. BJ Marshall E Sanders (I.F. 3.9).
117. Reinhard J, Basset C, Holton J, Binks M, Youinou P, **Vaira D**.
Image analysis method to assess adhesion of Helicobacter pylori to gastric epithelium using confocal Laser scanning microscopy
Journal of Microbiological Method 2000; 39: 179-187 (I.F. 2).
118. Menegatti M, Figura N, Farinelli S, Landi F, Acciardi C, Ricci C, Holton J, Gatta L, Crosatti M, Geminiani R, Polacci R, Miglioli M, **Vaira D**,
Helicobacter pylori seroconversion in asymptomatic blood donors. A five-years follow-up.
Digestive Disease and Sciences 2000; 45: 1653-59 (I.F. 2.5).
119. Savarino V, Landi F, Dulbecco P, Ricci C, Tesseri L, Biagini R, Miglioli M, Celle G, **Vaira D**.
Isotope Ratio mass-Spectrometry (IRMS) versus Laser-Assisted Ratio Analyser (LARA): a comparative study using two doses of ¹³C-urea and two test meals for pre- and post-treatment diagnosis of Helicobacter pylori infection.
Digestive Disease and Sciences 2000; 45: 2168: 74 (I.F. 2.5).
120. **Vaira D**, Ricci C, Menegatti M, Gatta L, Geminiani A, Miglioli M.
Clinical Role of Fecal antigen determination in the diagnosis of Helicobacter pylori.
Clinical Laboratory 2000; 46: 487-91. (I.F. 0.9)

121. **Vaira D**, Ricci C, Menegatti M, Acciardi C, Gatta L, Geminiani A, Miglioli M.
Diagnosis of *Helicobacter pylori* infection: faecal antigen determination.
Helicobacter pylori: Basic mechanisms to clinical cure 2000
Edited by Hunt RH, Tytgat GNJ.pg 115-122
- 2001**
122. **Vaira D**, Vakil N.
Blood, urine, stool, breath, money and *Helicobacter pylori*
Gut 2001; 48: 287-88.5 (I.F. 26.2)
123. **D. Vaira**, C. Ricci, M. Menegatti, L. Gatta, S. Berardi, A. Tampieri, M. Miglioli
Stool test for *Helicobacter pylori*.
American Journal of Gastroenterology 2001; 96: 1935-37 (letter) (I.F. 10.9)
124. Manes G, Balzano A, Iaquinto G, Ricci C, Piccirillo M, Giardullo N,
Todisco A, Lioniello M, **Vaira D**.
Accuracy of the stool antigen test in the diagnosis of *Helicobacter pylori* infection
in the pre-treatment assessment and in patients on omeprazole therapy
Alimentary Pharmacology & Therapeutics 2001; 15: 73-79 (I.F.7.4).
125. **D Vaira**, J Holton, Chiara Ricci, M Menegatti, L Gatta, Sonia Berardi, A. Tampieri,
M Miglioli
Review article: the transmission of *Helicobacter pylori* from stomach to stomach.
Alimentary Pharmacology & Therapeutics 2001; 15: 33-42 (I.F.7.3).
126. Fernando N, Holton J, Zulu I, **Vaira D**, Mwaba P, Kelly P.
Helicobacter pylori infection in an urban African population.
Journal of Clinical Microbiology 2001; 39: 1323-7 (I.F.5.4).
127. Fernando N, Perera N, **Vaira D**, Holton J
Helicobacter pylori in school children from the western province of Sri Lanka
Helicobacter 2001; 6: 169-174 (I.F. 4.3).
128. **Vaira D**, Gatta L, Ricci C, D'Anna L, Miglioli M.
Helicobacter pylori: diseases, tests and treatment
Digestive Liver Diseases 2001; 33: 788-94 (I.F.4.6).
129. Manes G, Balzano A, Iaquinto G, Ricci C, Piccirillo MM, Giardullo N,
Todisco A, Lioniello M, **Vaira D**.
Accuracy of the stool antigen test in post-eradication assessment of
Helicobacter pylori infection.
Digestive Disease Science 2001, 46: 2440-4. (I.F. 2.5).
130. **Vaira D**, Gatta L, Ricci C, D'Anna L, Miglioli M
How valuable is the application on Consensus guidelines in the management
of functional gastrointestinal disorders
Digestive Disease 2001, 19: 225-231 (I.F. 2.1)

131. Spigelman M, Barnes I, Holton J, **Vaira D**, Thomas MG.
Long-term DNA survival in ethanol- preserved archival material.
Annals of Royal College of Surgeon 2001; 83: 283-4 (**I.F. 1.7**).
132. Holton J, **Vaira D**.
Gastric Helicobacters.
Laboratory Diagnosis of Bacterial Infections, Edited by Nevio Cimolai 2001; 605-634.

2002

133. Vakil. N, **Vaira D**. Bugs, drugs and dyspepsia in primary care.
BMJ USA 2002; 2: 313-14. (**I.F. 43**)
134. **Vaira D**, Vakil N, Menegatti M, van't Hoff B, Ricci C, Gatta L, Gasbarrini G, Quina M, Pajares J, van Der Ende A, van der ulst R, Anti M, Duarte C, Gisbert J, Miglioli M, Tytgat G.
The stool antigen H test for the detection of Helicobacter pylori after eradication therapy.
Annals of Internal Medicine 2002; 136: 280-87 (**I.F. 15.4**)
135. Perri F, Manes G, Neri M, **Vaira D**, Nardone G
Helicobacter pylori Antigen Stool Test and ¹³C Urea Breath Test in patients after eradication treatments
American Journal of Gastroenterology 2002; 97: 2756-62 (**I.F. 10.9**)
136. **Vaira D**, Holton J, Ricci C, Basset C, Gatta L, Perna F, Tampieri A, Miglioli M.
Helicobacter pylori infection from pathogenesis to treatment: a critical reappraisal.
Alimentary Pharmacology & Therapeutics 2002; 16 (Suppl 4): 105-13 (**I.F. 9.5**).
137. **Vaira D**, Gatta L, Ricci C, Miglioli M.
Diagnosis of Helicobacter pylori infection.
Alimentary Pharmacology & Therapeutics 2002; 16: 16-23 (**I.F. 9.5**).
138. Palli D, Menegatti M, Masala G, Ricci C, Saieva C, Holton J, Gatta L, Miglioli M, **Vaira D**.
Helicobacter pylori infection, anti-cagA antibodies and peptic ulcer: a case-control study in Italy
Alimentary Pharmacology & Therapeutics 2002; 16:1015-20 (**I.F. 9.5**).
139. Voland P, Weeks DL, **Vaira D**, Prinz C, Sachs G.
Specific identification of three low molecular weight membrane-associated antigens of Helicobacter pylori.
Alimentary Pharmacology & Therapeutics 2002; 16:533-44 (**I.F. 9.5**).
140. Fernando N, Holton J, **Vaira D**, DeSilva M, Fernando D.
Prevalence of Helicobacter pylori in Sri Lanka as determined by PCR.
Journal of Clinical Microbiology 2002; 40:2675-6 (**I.F. 5.4**).
141. Figura N, Piomboni P, Ponzetto A, Gambera L, Lenzi C, **Vaira D**, Peris C, Lotano MR, Giannace R, Nardi M, Bianciardi L, Ranieri T, Valensin PE, Capitani S, Moretti E, Colapinto R, Baccetti B.
Helicobacter pylori infection and infertility
European Journal of gastroenterology & Hepatology 2002; 14:663-9 (**I.F.2.6**)

142. Figura N, Palazzuoli A, Faglia S, Lenzi C, Borrello F, Palazzuoli V, Nani R, Dal Canto N, De Regis F, **Vaira D**, Giannace R, Gennari C
The infection by Cag-A positive *Helicobacter pylori* strains is highly prevalent in patient with ischemic hearth disease.
Digestive Disease and Science 2002; 47:831-36. (I.F. 2.5)
143. Basset C, Holton J, **Vaira D**.
Helicobacter: a paradigm shift in peptic ulcer disease and more?
Science Progress 2002; 85:13-31
2003
144. **Vaira D**, Vakil N, Rugge M, Gatta L, Ricci C, Menegatti M, Leandro G, Holton J, Russo V, Miglioli M
The effect of *Helicobacter pylori* eradication on development of dyspepsia and reflux disease in healthy asymptomatic subjects
Gut 2003; 52: 1543- 47 (I.F. 26.2)
145. Sapone A, **Vaira D**, S. Trepidi, Perna F, Gatta L, Tampieri A, Ricci C, Paolini M, Miglioli M, Biagi GL, Cantelli-Forte G.
The clinical role of cytochrome P450 genotypes in *Helicobacter pylori* management.
American Journal of Gastroenterology 2003; 98: 1010-15 (I.F. 10.9)
146. Perna F, Gatta L, Figura N, Ricci C, Tampieri A, Holton J, Miglioli M, **Vaira D**
Metronidazole susceptibility for *Helicobacter pylori*
American Journal of Gastroenterology 2003; 98: 2157-61 (I.F. 10.9)
147. Gatta L, Vakil N, Ricci C, Osborn J, Tampieri A, Perna F, Miglioli M, **Vaira D**.
A rapid, low dose ¹³C Urea tablet for the detection of *Helicobacter pylori* infection before and after treatment
Alimentary Pharmacology & Therapeutics 2003; 17: 793-798 (I.F.9.5).
148. Basset C, Holton J, Ricci C, Gatta L, Tampieri A, Perna F, Miglioli M, **Vaira D**.
Diagnosis and treatment of *Helicobacter*. A 2002 Updated review.
Alimentary Pharmacology & Therapeutics 2003; 17: 88.5-97 (I.F. 9.5).
149. Leodolter A, **Vaira D**, Bazzoli F, Schütze K, Hirschl A, Mégraud F, Malfertheiner P
European multicentre validation trial of two new non-invasive tests for the detection of *H. pylori* antibodies: Urine-based ELISA and rapid urine test.
Alimentary Pharmacology & Therapeutics 2003; 18; 927-31 (I.F. 9.5).
150. Zullo A, **Vaira D**, Vakil N, Hassan C, Gatta L, Ricci C, De Francesco V, Menegatti M, Tampieri A, Perna, F, Rinaldi V, Perri, F, Papadia C, Fornari F, Pilati S, Mete LS, Merla A, Poti, R.
Marinone G, Ravioli A, Campo SMA, Faleo D, Ierardi E, Miglioli, M, Morini S.
High eradication rates for *Helicobacter pylori* with a new sequential treatment
Alimentary Pharmacology & Therapeutics 2003; 17: 719-26 (I.F. 9.5).
151. Gatta L, Ricci C, Tampieri A, **Vaira D**.
Non invasive techniques for the diagnosis of *Helicobacter pylori*.
Clinical Microbiology & Infection 2003; 9: 498-96

152. Gatta L, Perna F, Figura N, Ricci C, Holton J, D'Anna L, Miglioli M, **Vaira D.**
Esomeprazole versus omeprazole. Antimicrobial activity in vitro against Helicobacter pylori.
Journal of Antimicrobial Chemotherapy 2003; 51:439-42 (I.F. 4)
153. Gatta L, Ricci C, Stanghellini V, Ali' A, Menegatti M, Morselli Labate AM, Corinaldesi R, Miglioli M, **Vaira D.**
Best cut off values for 14C-urea breath tests for Helicobacter pylori detection.
Scandinavian Journal of Gastroenterology 2003; 38: 1144-8 (I.F. 1.7).
154. Dore MP, **Vaira D.**
Sheep rearing and Helicobacter pylori-implications for transmission of the infection (or sheep rearing and Helicobacter pylori infection- an epidemiological model of anthrozoosis).
Digestive Diseases and Sciences 2003; 35: 7-9 (I.F. 2.5).

- 155 Perna F, Figura N, Gatta L, Ricci C, Bernabucci V, **Vaira D**
Response to Dr Osato and Graham
American Journal of Gastroenterology 2004; 99: 2500 (I.F. 10.9)
156. Gatta L, Vakil N, Ricci C, Osborn JF, Tampieri A, Perna F, Miglioli M, **Vaira D**.
Effect of Proton Pump Inhibitors and Antacid Therapy on ¹³C-Urea Breath Tests
and Stool Test for *Helicobacter pylori* Infection
American Journal of Gastroenterology 2004; 99: 823-29 (I.F. 10.9)
157. Ricci C, Vakil N, M Rugge, Gatta L, Perna F, Osborn JF, Russo VM,
Tampieri A, Miglioli M, **Vaira D**.
Serological markers for gastric atrophy in asymptomatic subjects infected
with *Helicobacter pylori*.
American Journal of Gastroenterology 2004; 99: 1910-15 (I.F. 10.9)
158. Gatta L, Perna F, Ricci C, Osborn JF, Tampieri A, Bernabucci V, Miglioli M, **Vaira D**
A rapid Immunochromatographic assay for *Helicobacter pylori* in stool before and
after treatment
Alimentary Pharmacology & Therapeutics 2004; 20: 469-474 (I.F. 9.5).
159. C. Basset, J. Holton, L. Gatta, C. Ricci, V. Bernabucci, G. Liuzzi, **D. Vaira**
Helicobacter pylori infection: anything new should we know?
Alimentary Pharmacology & Therapeutics 2004; 20: 1-10 (I.F. 9.5).
- 160 Nardone G, Rocco A, **Vaira D**, Staibano S, Budillon A, Tatangelo F, Scialli MG,
Perna F, Salvatore G,
Di Benedetto M, De Rosa G, Patrignani P.
Expression of COX-2, mPGE synthase 1, MDR-1 (P-GP) and BCL-XL: a
molecular pathway of H pylori related-gastric carcinogenesis.
Journal of Pathology 2004; 202(3):305-12 (I.F. 5.2).
161. Lahner E, **Vaira D**, Figura N, Pillozzi E, Pasquali A, Severi C, Perna F,
Delle fave G, Annibale B.
Role of non-invasive tests (¹³C-urea Breath Test and Stool Antigen Test) as additional
tool in diagnosis of *Helicobacter pylori* infection in patients with atrophic body gastritis.
Helicobacter 2004; 4: 436-42 (I. F. 4.9)
162. **Vaira D**, Gatta L, Ricci C
Stool test for *Helicobacter pylori*
Digestive and Liver Disease 2004; 36: 446-7 (I.F.4.6)
163. Zullo A, Hassan C, Morini S, De Francesco V, Ierardi E, Panella C, Gatta L, **Vaira D**
Sequential therapy for *H. pylori*: an "aberrant" therapy ready for general use.
Digestive and Liver Disease 2004; 36: 852-853(I.F. 3.5)
164. Basset C, Holton J, Bazeos A, **Vaira D**, Bloom S
Are *Helicobacter* species and Enterotoxigenic *Bacteroides fragilis* involved in
Inflammatory Bowel Disease?
Digestive Disease and Sciences 2004; 49: 1425-32 (I.F. 2.5)

165. Vakil N. **Vaira D**

Non-Invasive tests for the diagnosis of Helicobacter pylori infection.
Diagnosis Updated 2004; X: 1-6.

2005

166. Gatta L, Zullo A, Perna F, Ricci C, De Francesco V, Tampieri A, Bernabucci V, Cavina, M, Hassan C, Ierardi E, Morini S, **Vaira D**.
A 10 days Levofloxacin base triple therapy in patients who failed two eradication courses
Alimentary Pharmacology & Therapeutics 2005; 22: 45-49 (I.F. 9.5).

167. Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V, Cavina, M, Ierardi E, Morini S, **Vaira D**.
High Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study
Alimentary Pharmacology & Therapeutics 2005; 21: 1419-24 (I.F. 9.5).

168. O'Mahony R, Basset C, Holton H, **Vaira D**, Roitt I.
Comparison of image analysis software packages in the assessment of adhesion of micro organism of mucosal epithelium using confocal laser scanning microscopy.
Journal of Microbiological Methods 2005; 61:105-126 (I.F. 2)

169. O'Mahony R, Al-Khtheeri H, Weerasekera D, Fernando N, **Vaira D**, Holton J, Basset C.
Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori.
World J Gastroenterol. 2005; 11(47):7499-507. (I: F: 5.3).

170. Manes G, Pieramico O, Perri F, **Vaira D**, Giardullo N, Romano M, Tardone G, Balzano A.
Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy.
Digestive Disease and Sciences 2005; 50: 443-48 (I.F. 2.5)

171. **Vaira D**, Gatta L, Ricci C, Tampieri A, Cavina, M, Bernabucci V, Miglioli M.
Peptic ulcer and Helicobacter pylori.
Postgraduate Medicine 2005; 17-22 (I: F: 2.5).

172. Salardi S, Cacciari E, Volta U, Santoni R, Ragni L, Elleri D, Cicognani A, **Vaira D**.
Growth and adult height in atypical celiac patients, with or without growth hormone deficiency.
Journal of Paediatric Endocrinology & Metabolism 2005; 18: 769-75 (I.F 1).

173. O'Mahony R, **Vaira D**, Holton J, Basset C.
Helicobacter pylori: current status and future prospects.
Science Progress 2004;87 (Pt 4):269-96.

174. Gatta L, Ricci C, Tampieri A, Osborn J, Perna F, Bernabucci V, **Vaira D**.
Accuracy of breath tests using low doses of ¹³C-urea to diagnose
Helicobacter pylori infection: A randomised controlled trial
Gut 2006; 55: 457-462 (I.F. 26.2)

2007

175. **Vaira D**, Zullo A, Vakil N, Gatta L, Ricci C, Perna P, Hassan C, Bernabucci V, Tampieri A, Morini S.
Sequential therapy versus Triple Therapy for *Helicobacter pylori* Eradication: a randomized trial.
Annals of Internal Medicine 2007; 146: 556-563 (I.F. 15.4)
176. **Vaira D**, Zullo A, Vakil N.
Sequential therapy: Minimizing risk and maximizing outcome.
Annals of Internal Medicine 2007; 147: 435-6. (I.F. 15.4)
177. Zullo A, De Francesco V, Hassan C, Morini S, **Vaira D**.
The sequential therapy regimen for *Helicobacter pylori* eradication.
Gut 2007; 56: 1353-57 (I.F. 26.2)
178. **Vaira D**, Perna F.
How useful is the rapid urease test for evaluating the success of *Helicobacter pylori* eradication therapy?
Nature Clinical Practice Gastroenterology & Hepatology 2007; 4: 600-01 (I.F. 5.3).
179. Gatta L, **Vaira D**, Sorrenti G, Zucchini A, Sama C, Vakil N.
Laryngeal symptoms and treatment for GERD. A systematic review and meta-analysis of the efficacy of proton pump inhibitors.
Alimentary Pharmacology & Therapeutics 2007; 25: 385-92. (I.F. 9.5).
180. Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S, **Vaira D**.
Primary antibiotic resistance in *Helicobacter pylori* strains isolated in Northern and Central Italy.
Alimentary Pharmacology & Therapeutics 2007; 25: 1429-34. (I.F. 9.5).
181. Annibale B, Lahner E, Santucci A, **Vaira D**, Pasquali A, Severi C, Mini R, Figura N, Delle Fave G.
CagA and VacA are immunoblot markers of past *Helicobacter pylori* infection in atrophic body gastritis.
Helicobacter 2007; 12: 23-30 (I.F. 4.3).
182. Ricci C, Holton J, **Vaira D**
Diagnosis of *Helicobacter pylori*: invasive and non- invasive tests
Best Practice & Research Clinical Gastroenterology 2007; 21: 229-313 (I.F. 4)
183. Perna F, Zullo A, Ricci C, Hassan C, Morini S, **Vaira D**.
Levofloxacin-based triple therapy for *Helicobacter pylori* retreatment: role of bacterial resistance.
Digestive Liver Diseases 2007; 39:1001-5 (I.F. 3.5).
184. Zullo A, **Vaira D**.
Updated on the treatment of patients with *Helicobacter pylori*. (Letter).
American Family Physician 2007; 1; 76: 633. (I.F. 6.7).
185. **Vaira D**, Ricci C, Lanzini A, Perna F, Romano A, Corinaldesi R.
How to proceed in H pylori-positive chronic gastritis refractory to first and second line eradication therapy.
Dig Dis. 2007;25:203-5 (I.F. 2.1).

186. Vakil N, **Vaira D.**
Sequential therapy for *Helicobacter pylori*: Time to make the switch?
Journal of American Medical Association 2008; 300: 1346-7 (I.F. 55)
187. Gatta L, Zullo A, Di Mario F, **Vaira D.**
Errors in a meta-analysis of treatment for *Helicobacter pylori* infection.
Annals of Internal Medicine 2008; 149: 686 (I.F. 15.4)
188. Vakil N, Zullo A, Ricci C, Hassan C, **Vaira D.**
Duplicate breath testing to confirm eradication of *Helicobacter pylori*:
incremental benefit and cost in 419 patients.
Alimentary Pharmacology & Therapeutics 2008; 28: 1304-8 (I.F. 9.5).
- 188.5. Romano M, Novene MR, Russo MI, Rocco A, Salerno R, Cozzolino D,
Pilloni AP, Tufano MA, **Vaira D.**, Nardone G.
Failure of first line eradication treatment significantly increases
prevalence of anti-microbial resistant *helicobacter pylori* clinical isolates.
J Clin Pathol, 2008; 61: 1112-15 (I.F. 2).
190. Salardi S, Volta U, Zucchini S, Fiorini E, Maltoni G, **Vaira D.**, Cicognani A.
The prevalence of celiac disease in children with type 1 diabetes mellitus
increased in the mid nineties: an 18-yr longitudinal study based on
anti-endomysial antibodies.
Journal of Paediatric Gastroenterology & Nutrition 2008; 46: 612-14. (I.F. 2.7).
191. Zullo A, Perna F, Ricci C, Hassan C, Tampieri A, De Francesco V, Morini S, **Vaira D.**
13C-urea breath test values and *Helicobacter pylori* eradication.
Digestive Diseases and Sciences 2008; 53: 370-75 (I.F. 2.5).
192. **Vaira D.**, Figura N, Bernardini G, Braconi D, Santucci A.
Diagnosis of *Helicobacter pylori* infection.
Medlab Magazine 3; 20-24.

193. Gatta L, Vakil N, Leandro G, Di Mario F, **Vaira D**.
Sequential therapy or triple therapy for *Helicobacter pylori*: systematic review and meta-analysis of randomized controlled trials in adult and children.
American Journal of Gastroenterology 2009; 104: 3069-79 (I.F. 10.9).
194. Zullo A, Hassan C, Andriani A, Cristofari F, De Francesco V, Ierardi E, Tomao S, Morini S, **Vaira D**.
Eradication therapy for *Helicobacter pylori* in patients with gastric MALT-Lymphoma: a Pooled-data Analysis.
American Journal of Gastroenterology 2009, 104: 1932-7 (I.F. 10.9).
195. Younson J, O'Mahony R, Liu H, Grant S, Campion C, **Vaira D**, Jennings L, Kelly CG, Roitt IM, Holton J.
A human domain antibody and Lewis^b-glycoconjugate that inhibit binding of *Helicobacter pylori* to Lewis^b receptor and inhibit bacterial adhesion to human gastric epithelium.
The Journal of Infectious Disease 2009; 200:1574-82 (I.F. 4.5).
196. De Francesco V, Zullo A, Ierardi E, Giorgio F, Perna F, Hassan C, Pannella C, **Vaira D**.
The A2143G point mutation of Clarithromycin resistance affects H. pylori eradication.
Journal of Clinical Gastroenterology 2009; 43: 386 (I.F. 2.7).
197. **Vaira D**, Gatta L, Ricci C, Di Mario F, Lanzini A.
Accuracy of urea breath tests tablets after 10 minutes compared to standard 30 minutes to diagnose and monitoring *Helicobacter pylori* infection: a randomised controlled trial.
Journal of Clinical Gastroenterology 2009; 43: 693-94 (I.F. 2.7).
198. De Francesco V, Zullo A, Ierardi E, **Vaira D**.
Minimal inhibitory concentration (MIC) values and different point mutations in the 23S rRNA gene for Clarithromycin resistance in *Helicobacter pylori*.
Digestive and Liver Disease 2009; 41: 610-611 (I.F. 3.5).
199. **Vaira D**, Zullo A, Hassan C, Fiorini G, Vakil N.
Sequential therapy for *Helicobacter pylori* eradication: the time is now!
Therapeutic Advances in Gastroenterology 2009; 2: 317-322.

200. Gatta L, Di Mario F, **Vaira D**.
Treatment of *Helicobacter pylori* infection.
Gut 2010; 59: 1300-1. (I.F. 26.2) (letter)
201. Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, Stolte M, Morini S, **Vaira D**.
Effects of *Helicobacter pylori* eradication on early-stage gastric mucosa associated lymphoid tissue lymphoma.
Clin Gastroenterol Hepatol 2010; 8: 105-110. (I.F. 12.2).
202. Zullo A, Hassan C, D'Ercole C, De Francesco V, **Vaira D**.
Clarithromycin or Levofloxacin in the sequential therapy for *H. pylori* eradication?
Alimentary Pharmacology & Therapeutics 2010; 11:1249-50 (I.F. 9.5) (Letter)
203. **Vaira D**, Vakil N, Gatta L, Ricci C, Perna F, Saracino I, Fiorini G, Holton J.
Accuracy of a new ultra fast rapid urease test to diagnose *Helicobacter pylori* infection in 1000 consecutive patients.
Aliment Pharmacology Ther 2010; 31: 331-338 (I.F. 9.5).
204. De Francesco V, Zullo Ierardi E, Giorgio F, Perna F, Hassan C, Morini S, Pannella C, **Vaira D**.
Phenotypic and genotype *H. pylori* Clarithromycin resistance and therapeutic outcomes: benefit and limits.
Journal of Antimicrobial Chemotherapy 2010; 65: 327-332 (I.F. 4)
205. Gatta L, Vakil N, **Vaira D**, Pilotto A, Curlo M, Comparato G, Leandro G, Ferro U, Lera M, Milletti S, Di Mario F.
Efficacy of 5-ASA in the treatment of colonic diverticular disease.
Journal of Clinical Gastroenterology 2010; 44:113-9 (I.F. 2.7)
206. **Vaira D**, Gatta L, Ricci C, Perna F, Saracino I, Fiorini G, Castelli V, Holton J.
A comparison among three rapid urease tests to diagnose *Helicobacter pylori* infection in 375 consecutive dyspeptic.
Internal and Emergency Medicine 2010; 1: 41-47 (I.F. 3.8).
207. Gatta L, Moayyedi P, Tosetti C, Vakil N, Ubaldi E, Barsanti P, Fiorini G, Castelli, Gargiulo C, Lucarini P, Lera M, Kaio E, Di Mario F, **Vaira D**.
A validation study of the Italian Short-Form Leeds Dyspepsia Questionnaire
Internal and Emergency Medicine 2010; 5: 501-506 (I.F. 3.8).
208. Perna F, **Vaira D**.
A new 24 hour Enzyme Immune Assay-culture based method for *Helicobacter pylori* Chemosusceptibility.
Journal of Clinical Pathology 2010; 63: 648-51 (I.F. 2).
209. Fernando N, Torres P, **Vaira D**, Holton J.
Colonization by *Helicobacter pylori* of leprosy patients in Spain: immunomodulation to low molecular weight antigens of *H pylori*.
Memorias do Instituto Oswaldo Cruz 2010; 105: 682-6 (I.F. 2.5)

210. De Francesco V, Zullo A, Perna F, Giorgio F, Hassan C, Vannella L, Cristofari F, Panella C, **Vaira D**, Ierardi E.
H. pylori antibiotic resistance and 13C urea breath test values.
J Med Microbiol. 2010; 59: 588-91 (I.F. 2)
211. Caselli M, Holton J, Boldrini P, **Vaira D**, Calò G.
Morphology of segmented filamentous bacteria and their patterns of contact with the follicle-associated epithelium of the mouse terminal ileum: implications for the relationship with the immune system.
Gut Microbes 2010; 6: 367-72.
212. Gatta L, **Vaira D**, Fiorini G, Borghi C.
Proton pump inhibitors and antiplatelet drugs in clinical cardiology.
Cardiology and Clinical Practice 2010, Volume 2, Number 2, 1 May 2010, pp. 75-83(9)
213. Abadi AT, Taghaei T, **Vaira D**.
Considerable use of furazolidone in Iran.
Saudi J Gastroenterol 2010; 16: 308-9. (letter)

214. Zullo A, De Francesco V, **Vaira D**.
Sequential therapy for H pylori eradication: is Levofloxacin better?
Gut 2011; 60: 1604 (**I.F. 26.2**) (**letter**)
215. Gatta L, Di Mario F, **Vaira D**, Franzé A, Rugge M, Pilotto A, Lucarini P, Lera M, Scarpignato C.
Quantification of serum levels pepsinogen and gastrin to assess eradication of *Helicobacter pylori*.
Clin Gastroenterol Hepatol 2011;9:440-42 (**I.F. 7.7**).
216. Abadi ATB, Ajami A, Taghvaei T, Mobarez AM, **Vaira D**.
Highly Correlation of *babA₂*-Positive Strains of *Helicobacter pylori* with the presence of Gastric Cancer
Internal and Emergency Medicine 2011; (**I.F. 2.3**).
217. **Vaira D**, Gatta L, Ricci C, Castelli V, Fiorini G, Kaio E, Lanzini A.
Gastroesophageal Reflux Disease and Barrett's Esophagus.
Internal and Emergency Medicine 2011; 6:299-306 (**I.F. 2.3**).
218. Gatta L, Di Mario F, **Vaira D**, Franzé A, Rugge M, Pilotto A, Lucarini P, Lera M, Fiorini G, Castelli V, Kaio E, Scarpignato C.
Helicobacter pylori eradication: Are we really all equal? A controlled study in native and immigrant population.
Internal and Emergency Medicine 2011; 6: 35-39 (**I.F. 2.3**).
219. Caselli M, **Vaira D**, Calò G, Papini F, Holton J, Vaira D.
Structural bacterial molecules as potential candidates for an evolution of the classical concept of Probiotics.
Advance in Nutrition 2011; 2:372-76

2012

220. Gatta L, Vakil N, **Vaira D.**
Treatment of Helicobacter Pylori in Latin America
The Lancet 2012; 379: 407-09 (letter) (I.F. 88.5)
221. Pacifico L, Osborn J F, Anania C, **Vaira D**, Olivero E, Chiesa C.
Bismuth-based therapy for Helicobacter pylori eradication in children
Alimentary Pharmacology & Therapeutics 2012; 35:1010-26 (I.F. 9.5)
222. Zullo A, Ridola L, Hassan C, Bruzzese V, Papini F, **Vaira D.**
Glaucoma and Helicobacter pylori: eyes wide shut?
Digestive and Liver Disease 2012; 44: 627-28. (I.F.4.6).
223. Francavilla R, Zullo A, **Vaira D**
How often do you fail to take all of your medication?
Journal of Paediatric Gastroenterology & Nutrition. 2012; 55(3):338 (letter) (I.F. 2.7)
224. Gatta L, Di Mario F, Curlo M, **Vaira D** , Pilotto A, Lucarini P, Lera M, Enkleda K, Franzé A, Scarpignato C.
Long-term treatment with mesalazina in patients with symptomatic uncomplicated diverticular disease.
Internal and Emergency Medicine 2011; 7: 133-37 (I.F. 3.8).
226. Parente F, Marino B, Ilardo A, Fracasso P, Zullo A, Hassan C, Moretti R, Cremaschini M, Ardizzoia A, Perna F, **Vaira D.**
A combination of faecal tests for the detection of colon cancer: a new strategy for appropriate selection of referrals to colonoscopy ? A prospective multicenter italian study.
European Journal of Gastroenterology & Hepatology 2012;10: 1145-52 (I.F.2.6)
227. Fiorini G, Zullo A, Gatta L, Castelli V, Ricci C, Papini F, **Vaira D.**
Newer agents for Helicobacter pylori eradication
Clinical and Experimental Gastroenterology 2012;5: 109-112.
228. Caselli M, Holton J, Cassol F, Ricci C, Gatta L, Castelli V, Fiorini G, Saracino I, Vaira G, Papini F, Calò G, **Vaira D.**
Recombinant probiotics and their potential in human health
International Journal of Probiotics and Prebiotics 2012; 7: 53-58.

2013

228. Gatta L, Vakil N, **Vaira D.** Scarpignato C.
Global eradication rates for Helicobacter pylori infection: systematic review and meta- analysis of sequential therapy.
British Medical Journal 2013; 347:f4587 (I.F. 43).
229. Fiorini G. Vakil N. Zullo A Saracino I.M., Castelli V, Ricci C, Zaccaro C, Gatta L **Vaira D.**
Culture based triple therapy using levofloxacin or rifabutin in patients who fail initial Therapy
Clin Gastroenterol Hepatol 2013;11:507-10 (I.F.11.4).

230. Osborn JF, Cattaruzza MS, Ferri AM, De Angelis F, Renzi D, Marani A, **Vaira D.**
How long will it take to reduce gastric cancer incidence by eradicating *Helicobacter pylori* infection?
Cancer prevention research 2013; 6(7): 695-700(I.F. 2.6).
231. Zullo A, Hassan C, Ridola R, De Francesco V, Rossi L, Tomao S, **Vaira D.**
Genta RM
Eradication Therapy in *H. pylori* Negative, Gastric Low-grade Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Patients. *A Systematic Review.*
Journal of Clinical Gastroenterology 2013; 47(10):824-7(I.F. 2.7).
232. Vakil N, **Vaira D.**
Treatment for *H. pylori* infection: new challenges with anti-microbial resistance
Journal of Clinical Gastroenterology 2013; 47: 383-88 (I.F. 2.7).
233. Zullo A, De francesco V, Hassan C, Ridola L, Repici A, Bruzzese V, **Vaira D.**
Modified sequential therapy regimens for *Helicobacter pylori* eradication: a systematic review."
Digestive and Liver Disease 2013; 1:18-22. (I.F. 3.5).
234. Zullo A, Hassan C, Ridola L, De Francesco V, **Vaira D.**
Standard triple and sequential therapies for *Helicobacter pylori* eradication: an update.
European Journal of Internal Medicine 2013; 1: 16-9. (I.F. 6.1)
235. Abadi ATB, Ajami A, Taghvaei T, Mobarez AM, **Vaira D.**
Highly Correlation of *babA2*-Positive Strains of *Helicobacter pylori* with the presence of Gastric Cancer
Internal and Emergency Medicine 2013 Sep;8(6):497-501. (I.F. 3.8).
236. Fiorini G, Zullo A, Castelli V, Lo Re G, Holton J, **Vaira D.**
Role of *helicobacter pylori* infection in the thyroid diseases
Journal of Gastrointestinal and Liver Diseases 2013 Sep;22(3):261-3 (I.F. 2)
237. Fiorini G, Zullo A, Castelli V, Lo Re G, Holton J, **Vaira D.**
Role of *helicobacter pylori* infection in the thyroid diseases
Journal of Gastrointestinal and Liver Diseases 2013 Sep;22(3):261-3 (I.F. 2)
238. Saracino I, Zaccaro C, Lo Re G, **Vaira D.**, Holton J.
The effects of two novel copper-based formulations on *Helicobacter pylori*
Antibiotics 2013; 2: 265-273.
239. Saracino I, Zaccaro C, Lo Re G, **Vaira D.**, Holton J.
The effects of two novel copper-based formulations on *Helicobacter pylori*
Antibiotics 2013; 2: 265-273.
240. Fiorini G, Zullo A, Castelli V, Ricci C, G. Lo Re, Saracino IM, Zaccaro C, Verardi FM, Reggi A, **Vaira D.**
Therapy for *h. pylori*: current concepts.
Open Journal of Gastroenterology 2013;3: 38-41.

2014

241. O'Connor A., Vaira D., Gisbert JP., O'Morain C.
Treatment of *Helicobacter pylori* infection 2014.
Helicobacter. 2014 Sep; 19 Suppl 1:38-45. (I.F. 4.3) **Q1**
242. Figura N, Palazzuoli A, Vaira D., Campagna M, Moretti E, Iacopini F, Giordano N, Clemente S, Nuti R, Ponzetto A.
Cross-sectional study: CagA-positive *Helicobacter pylori* infection, acute coronary artery disease and systemic levels of B-type natriuretic peptide.
Journal of Clinical Pathology 2014 Mar;67(3):251-7 (I.F. 2). **Q1**
243. Vaira D.
Diagnosing small bowel malabsorption
Internal and Emergency Medicine 2014 Feb;9(1):1-2 (I.F. 3.8). **Q2**
244. De Francesco V, Zullo A, Giorgio F, Saracino I, Zaccaro C, Hassan C, Ierardi E, Di Leo A, Fiorini G, Castelli V, Vaira D.
Change of point mutations in the *H. pylori* rRNA associated with clarithromycin resistance in Italy.
Journal of Medical Microbiology 2014 Mar;63(Pt 3):453-7 (I.F. 2) **Q1**
245. Zullo A, Hassan C, De Francesco V, Repici A, Manta R, Toamo S, Annibale B, Vaira D.
Helicobacter pylori and functional dyspepsia: an unsolved issue?
World J Gastroenterol 2014; 20: 8597-63. (I.F. 5.4) **Q1**

2015

246. Vaira D.
Changing prevalence of *Helicobacter pylori* infection and peptic ulcer among dyspeptic patients.
Intern Emerg Med. 2015 Oct;10(7):763-4. (I.F. 3.8) **Q2**
247. Fiorini G, Bland JM, Hughes E, Castelli V, Vaira D.
A systematic review on drugs absorption modifications after eradication in *Helicobacter pylori* positive patients undergoing replacement therapy.
J Gastrointest Liver Dis. 2015 Mar;24(1):95-100. (I.F. 2) **Q2**

2016

248. De Francesco V, Ridola L, Hassan C, Bellesia A, Alvaro D, **Vaira D**, Zullo A. Two-week triple therapy with either standard or high-dose Esomeprazole for first-line H pylori eradication. J Gastrointest Liver Dis 2016; 25: 147-50(I.F. 2). **Q2**
249. Fiorini G, Ribichini D, Pasquali R, **Vaira D**. In vivo dissolution of levothyroxine soft gel capsules. Intern Emerg Med. 2016; 11: 1151-52.(I.F. 3.8). **Q2**

2017

250. ZulloA, De Francesco V, **Vaira D**. Is double-dose Esomeprazole with bismuth really safe? Am J Gastroenterol 2017; 112: 188.54-95 .(I.F. 10.9). **Q1**
251. Ponzetto A, Holton J, **Vaira D**. Years of life could be saved by preventing HCC. Alimentary Pharmacology & Therapeutics 2017; 45:373-79 (I.F. 9.5) **Q1**
252. Beckman E, Saracino I, Fiorini G, Clark C, Slepnev V, Patel D, Gomez C, Ponaka R, Elagin E, **Vaira D**. A Novel stool PCR Test for Helicobacter pylori may Predict Clarithromycin Resistance and Patient Eradication at a High Rate. J Clin Microbiol 2017; 55: 2400-05 (I.F. 5.4). **Q1**
253. Fiorini G, Saracino IM, Zullo A, Gatta L, Pavoni M, **Vaira D**. Rescue therapy with bismuth quadruple regimen in patients with Helicobacter pylori-resistant strains. Helicobacter 2017;22; .(I.F. 4.3). **Q1**
254. Ribichini D, Fiorini G, Repaci A, **Vaira D**, Pasquali P. Tablet and oral liquid L-thyroxine formulation in the treatment of naïve hypothyroid patients with Helicobacter pylori infection. Endocrine 2017; 57: 394-401 . (I.F. 4.7) **Q2**
255. Zaccaro C, Saracino IM, Fiorini G, Figura N, Holton J, Castelli V, Pesci V, Gatta L, **Vaira D**. Power of screening tests for colorectal cancer enhanced by high levels of M2-PK in addition to FOBT. Intern Emerg Med. 2017;12: 333-39.(I.F. 3.8). **Q2**

2018

256. Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino IM, Ricci C, **Vaira D**. Impact of primary antibiotic-resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: Lesson from 5 years' study on a large number of strains. Alimentary Pharmacology & Therapeutics 2018; 47:1261-69 (I.F. 9.5) **Q1**
257. **Vaira D**., Ponzetto A. Hepatic Encephalopathy and Helicobacter pylori. Digestive Disease and Sciences 2018 May;63(5):1368-1369 (I.F. 2.5). **Q2**
258. Fiorini G, Zullo A, Saracino IM, Pavoni M, **Vaira D**. Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010-2016. S Scand J Gastroenterol. 2018 Jun;53(6):661-664(I.F. 1.7)
259. Zullo A, Manta R, De Francesco V, Fiorini G, Iahner E, **Vaira D**, Annibale B. Cameron lesions: a still overlooked diagnosis. Case Report and systematic review of literature

2019

263. De Francesco V, Zullo A, Fiorini G, Saracino IM, Pavoni M **Vaira D.**
Role of MIC levels of resistance to clarithromycin and metronidazole in
Helicobacter pylori eradication.
J Antimicrob Chemother 2019; 3: 772-74. (I.F. 4) **Q1**
- 264 Zullo A, Manta R, De Francesco V, Fiorini H, Hassan C, Vaira D.
Diagnostic yield of upper endoscopy according to appropriateness: a
Systematic review.
Digestive and Liver Disease 2019; 51; 335-39. (I.F.4.6). **Q2**
265. D'Amico F, Fiorini G, Tursi A, Saracino IM, Pavoni M, Danese S, **Vaira D.**
Efficacy of a New regime patients with symptomatic
uncomplicated diverticular disease (SUDD): a prospective observational
Study.
J Gastrointest Liver Dis 2019; 28: 49-52. (I.F. 2). **Q2**
266. Zullo A, Fiorini G, Scaccianoce G, Portincasa P, De Francesco V, Vassallo R,
Urban F, Monica F, Mogavero G, Amato A, **Vaira D.**
Sequential therapy for first-line Helicobacter pylori eradication: 10- or 14- day
regimen?
J Gastrointest Liver Dis 2019; 28: 11-14.(I.F. 2). **Q2**
- 267 Zullo A, Gatta L, Vassallo R, De Francesco V, Manta R, Monica F, Fiorini G,
Vaira D.
Paradigm shift: the Copernican revolution in diverticular disease.
Ann Gastroenterol 2019;32: 541-553. (I.F. 2.2) **Q2**

2020

268. European Registry on Helicobacter pylori management (Hp-EuReg):Patterns and trends in
first-line empirical eradication prescription and outcomes of 5 years and 21,533 patients
Gut 2020 Jan;70(1):40-54. doi: 10.1136/gutjnl-2020-321372. . (I.F. 26.2) **Q1**
269. Fiorini G, Saracino IM., Zullo A, Pavoni M., Saccomanno L., Lazzarotto T.,
Cavallo R., Antonelli G., **Vaira D.**
Antibiotic resistance and therapy for H.pylori infection in immigrant patients managed in
Italy.
Journal of Clinical Medicine 2020 May 1;9(5):1299. doi: 10.3390/jcm9051299. (I.F. 5.4) **Q1**
270. Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L,
Ortuño J, Gomez-Rodriguez BJ, Pinto RM, Areia M, Perona M, Nuñez O, Romano M,
Gerarda Gravina A, Pozzati L, Fernandez-Bermejo M, Venerito M, Malfertheiner P,
Fernandez-Salazar L, Gasbarrini A, Vaira D, Puig I, Megraud F, O'Morain C, Gisbert JP.
European Registry on Helicobacter pylori Management: single-capsule bismuth quadruple
therapy is effective in real-world clinical practice.
United European Gastroenterol J. 2020 Nov 11:2050640620972615. doi:
10.1177/2050640620972615. Epub ahead of print. PMID: 33176617. (I.F. 6.9)
271. Saracino IM., Pavoni M., Saccomanno L., Fiorini G, Pesci V, Foschi C, Piccirilli G,
Beranardini G, Holton J, Figura N, Lazzarotto T. Borghi C, **Vaira D.**
Antimicrobial efficacy of five probiotic strains against H.pylori.
Antibiotics 2020, 81, pp. 50-53. (IF 5.2) **Q2**
272. Saracino IM, Fiorini G, Zullo A, Pavoni M, Saccomanno L, **Vaira D.**
Trends in primary antibiotic resistance in H pylori strains isolated in Italy between 2009 and

2019.

Antibiotics 2020 Jan 13;9(1):26. doi: 10.3390/antibiotics9010026 (IF 5.2) Q2

273. Saracino IM., Pavoni M., Zullo A., Fiorini G., Saccomanno L., Lazzarotto T., Cavallo R., Antonelli G., Vaira D.
Antibiotic resistance and therapy outcome in H.pylori eradication failure patients
Antibiotics 2020 Mar 13;9(3):121. doi: 10.3390/antibiotics9030121. (IF 5.2) Q2
274. Saracino IM., Pavoni M., Zullo A., Fiorini G., Saccomanno L., Lazzarotto T., Cavallo R., Antonelli G., Borghi C, Vaira D.
Rescue therapies for H. pylori infection in foreign patients treated in Italy.
Journal of Clinical Gastroenterology 2020; Clin Gastroenterol 2021 Nov-Dec;55(10):865-868. (I.F. 2.7)
275. Saracino IM., Pavoni M., Zullo A., Fiorini G., Saccomanno L., Lazzarotto T., Antonelli G. Cavallo R, Borghi C, **Vaira D.**
Rifabutin-based triple therapy or bismuth-based quadruple regimen as rescue therapies for Helicobacter pylori infection
European Journal of Internal Medicine 2020; Volume 81, Pages 50-53 (IF 4.3) Q2
276. Opekun AR., Zierold C., Rode A., Blocki F.A., Fiorini G., Saracino IM., Vaira D., Sutton FM.
Clinical performance of automated liaison meridian H pylori SA stool antigen test
BioMed Research International 2020; 19: 188.55-19. (I.F. 2.3) Q2
277. Fiorini G., Saracino I.M Pavoni M. Saccomanno L Vaira D.
Efficacy of a new nutraceutical formulation (CHETOGED) in patients with nonerosive reflux (NERD): a prospective observational study.
Intern Emerg Med. 2017;12: 333-39. 2020 (I.F. 3.8). Q2
278. Zullo A, Manta R., DE francesco V., Manfredi G., Buscarini E, Fiorini G., Vaira D., Marmo R.
Endoscopic submucosal dissection of gastric neoplastic lesions in western countries: systematic review and metanalysis Eur J Gastroenterol Hepatol 2021 Nov 1;33(11):e1-e6. doi: 10.1097/MEG.0000000000001886. (IF 2.6) Q2
279. Federico BARDAZZI, Michela MAGNANO, Giulia FIORINI, Dino VAIRA, Giulia ODORICI, Gabriele BERTUSI, Annalisa PATRIZI. Helicobacter Pylori infection in psoriatic patients during biological therapy. 2020 Feb 05. Giornale Italiano di Dermatologia e Venereologia. 2020 Feb 5. doi: 10.23736/S0392-0488.19.06410-1 (I.F. 2) Q3
280. Zullo A, Fiorini G, Bassotti G, Bacchetti F, Monica F, Macor D, Paoluzi OA, Scaccianoce G, Portincasa P, De Francesco V, Lorenzetti R, Saracino IM, Pavoni M, **Vaira D.**
Upper endoscopy in patients with extra-oesophageal reflux symptoms: A multicenter study. GE Port J Gastroenterol 2020, 27(5), pp. 312-317 (I.F. 0.6) Q3

2021

281. Nyssen OP, Bordin D, Tepes B, Pérez-Aisa Á, **Vaira D**, Caldas M, Bujanda L, Castro-Fernandez M, Lerang F, Leja M, Rodrigo L, Rokkas T, Kupcinskis L, Pérez-Lasala J, Jonaitis L, Shvets O, Gasbarrini A, Simsek H, Axon ATR, Buzás G, Machado JC, Niv Y, Boyanova L, Goldis A, Lamy V, Tonkic A, Przytulski K, Beglinger C, Venerito M, Bytzer P, Capelle L, Milosavljević T, Milivojevic V, Veijola L, Molina-Infante J, Vologzhanina L, Fadeenko G, Ariño I, Fiorini G, Garre A, Garrido J, F Pérez C, Puig I, Heluwaert F, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021 Jan;70(1):40-54. doi: 10.1136/gutjnl-2020-321372. Epub 2020 Sep 21. PMID: 32958544. (I.F. 26.2)
282. Nyssen OP, Vaira D, Aisa ÁP, Rodrigo L, Castro-Fernandez M, Jonaitis L, Tepes B, Vologzhanina L, Caldas M, Lanas A, Lucendo AJ, Bujanda L, Ortuño J, Barrio J, Huguet JM,

Voynovan I, Lasala JP, Sarsenbaeva AS, Fernandez-Salazar L, Molina-Infante J, Jurecic NB, Areia M, Gasbarrini A, Kupčinskas J, Bordin D, Marcos-Pinto R, Lerand F, Leja M, Buzas GM, Niv Y, Rokkas T, Phull P, Smith S, Shvets O, Venerito M, Milivojevic V, Simsek I, Lamy V, Bytzer P, Boyanova L, Kunovský L, Beglinger C, Douberis M, Marlicz W, Goldis A, Tonkić A, Capelle L, Puig I, Megraud F, Morain CO, Gisbert JP; Hp-EuReg Investigators. Empirical second-line therapy in 5,000 patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). *Clin Gastroenterol Hepatol*. 2022 Oct;20(10):2243-2257. doi: 10.1016/j.cgh.2021.12.025. Epub 2021 Dec 23. PMID: 34954341. (I.F. 12.2)

- 283 Adverse event profile during the treatment of Helicobacter pylori: a real world experience on 22,000 patients from the European Registry on H. pylori Management (Hp-EuReg). *American Journal of Gastroenterology* 2021. Jun 1;116(6):1220-1229. doi: 10.14309/ajg.0000000000001246 (I.F. 10.9)
- 284 Saracino, Ilaria M*; Pavoni, Matteo*; Zullo, Angelo; Fiorini, Giulia; Lazzarotto, Tiziana; Borghi, Claudio; **Vaira, Dino**. Next Generation Sequencing for the Prediction of the Antibiotic Resistance in Helicobacter pylori: A Literature Review. *Antibiotics* 2021, 10, no. 4: 437. <https://doi.org/10.3390/antibiotics10040437> (I.F. 4.6)
- 285 De Francesco, V.; Zullo, A.; Gatta, L.; Manta, R.; Pavoni, M.; Saracino, I.M.; Fiorini, G.; **Vaira, D.** Rescue Therapies for H. Pylori Infection in Italy. *Antibiotics* 2021, 10(5), 525; <https://doi.org/10.3390/antibiotics10050525> (I.F. 4.6)
287. Nyssen OP, Perez-Aisa A, Castro-Fernandez M, Pellicano R, Huguet JM, Rodrigo L, Ortuñ J, O, Gomez-Rodriguez BJ, Pinto RM, Areia M, Perona M, Nuñez O, Romano M, Gravina AG, Pozzati L, Fernandez-Bermejo M, Venerito M, Malfertheiner P, Fernandez-Salazar L, Gasbarrini A, **Vaira D**, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg investigators. European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice. *United European Gastroenterol J*. 2021 Feb;9(1):38-46. doi: 10.1177/2050640620972615. Epub 2021 Feb 11. PMID: 33176617; PMCID: PMC8259339 (I.F. 6.9)
288. Caldas, M., et al. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. *Antibiotics (Basel)*, 10(1), 13. IF 4.639 (I.F. 4.6).
- 288.5. Caldas M. et al. The role of statins on Helicobacter pylori eradication: results from the European Registry on the Management of H.pylori (Hp-EuReg). *Antibiotics* 2021, 10 (8) 965 (I.F. 4.6)
290. Resina E. et al Rescue therapies with furazolidone in patients with at least five eradication treatment failures and multiresistant H.pylori infection. *Antibiotics* 2021, 10 (9) 1028. (I.F. 4.6)
291. Bujanda L., Vaira D., Saracino I.M., Fiorini G. et al Antibiotic resistance prevalence and trends in patients infected with helicobacter pylori in the period 2013-202: results from the European registry on helicobacter pylori management (Hp-EuReg). *Antibiotics* 2021 IF 4.639 2021 Sep 1;10(9):1058. doi: 10.3390/antibiotics10091058 (I.F. 4.6)
292. Collatuzzo G, Fiorini G, Vaira D, Violante F, Farioli A, Boffetta P. The role of the occupational physician in controlling gastric cancer attributable to Helicobacter pylori infection: A review. *Preventive Medicine Reports*, Volume 24, 2021, 101527, ISSN 2211-3355. (I.F. 2.5)
293. Zullo A, Manta R., De francesco V. IM Saracino Fiorini G., Gatta L, **Vaira D**. H.pylori eradication following first-line treatment failure in Europe: what and when chose among different standard regimens? A systematic review. *European Journal of Gastroenterology & Hepatology* 2021 Dec 1;33(1S Suppl 1):e66-e70. (IF 2.6) Q2

294. Diego Burgos-Santamaría, Olga P Nyssen, Antonio Gasbarrini, Dino Vaira, Ángeles Pérez-Aisa, Luís Rodrigo, Rinaldo Pellicano, Alma Keco-Huerga, Manuel Pabón-Carrasco, Manuel Castro-Fernandez, Doron Boltin, Jesus Barrio, Perminder Phull, Juozas Kupcinskis, Laimas Jonaitis, Inmaculada Ortiz-Polo, Bojan Tepes, Alfredo J Lucendo, José María Huguet, Miguel Areia, Natasa Brglez Jurecic, Maja Denkovski, Luís Bujanda, June Ramos-San Román, Antonio Cuadrado-Lavín, Judith Gomez-Camarero, Manuel Alfonso Jiménez Moreno, Angel Lanas, Samuel Jesús Martínez-Dominguez, Enrique Alfaro, Ricardo Marcos-Pinto, Vladimir Milivojevic, Theodore Rokkas, Marcis Leja, Sinead Smith, Ante Tonkić, György Miklós Buzás, Michael Douberis, Marino Venerito, Frode Lerang, Dmitry S Bordin, Vincent Lamy, Lisette G Capelle, Wojciech Marlicz, Daniela Dobru, Oleksiy Gridnyev, Ignasi Puig, Francis Mégraud, Colm O'Morain, Javier P Gisbert On behalf of the Hp-EuReg Investigators.
Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg). *Gut* 2022;0:1–19. doi:10.1136/gutjnl-2022-328232. **(I.F. 26.2)**
295. Burgos-Santamaría D, Nyssen OP, Gasbarrini A, Vaira D, Pérez-Aisa Á, Rodrigo L, Pellicano R, Keco-Huerga A, Pabón-Carrasco M, Castro-Fernandez M, Boltin D, Barrio J, Phull P, Kupcinskis J, Jonaitis L, Ortiz-Polo I, Tepes B, Lucendo AJ, Huguet JM, Areia M, Jurecic NB, Denkovski M, Bujanda L, Ramos-San Román J, Cuadrado-Lavín A, Gomez-Camarero J, Jiménez Moreno MA, Lanas A, Martínez-Dominguez SJ, Alfaro E, Marcos-Pinto R, Milivojevic V, Rokkas T, Leja M, Smith S, Tonkić A, Buzás GM, Douberis M, Venerito M, Lerang F, Bordin DS, Lamy V, Capelle LG, Marlicz W, Dobru D, Gridnyev O, Puig I, Mégraud F, O'Morain C, Gisbert JP; Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg). *Hp-EuReg Investigators. Gut*. 2022 Dec 5;gutjnl-2022-328232. doi: 10.1136/gutjnl-2022-328232. Online ahead of print. PMID: 36591610 **(I.F. 26.2) Q1**
296. Gatta L, Nyssen OP, Fiorini G, Saracino IM, Pavoni M, Romano M, Gravina AG, Granata L, Pellicano R, Gasbarrini A, Di Leo A, Losurdo G, Franceschi F, Nardone G, Rocco A, Dore MP, Farinati F, Ghisa M, Bellini M, Holton J, Puig I, Vaira D, Borghi C, Mégraud F, O'Morain C, Gisbert JP. Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management. *United European Gastroenterol J*. 2023 Feb;11(1):103-113. doi: 10.1002/ueg2.12348. Epub 2022 Dec 23. PMID: 36565017 Free PMC article. **(I.F. 6.9)**
297. Nyssen OP, Vaira D, Pérez Aisa Á, Rodrigo L, Castro-Fernandez M, Jonaitis L, Tepes B, Vologzhanina L, Caldas M, Lanas A, Lucendo AJ, Bujanda L, Ortuño J, Barrio J, Huguet JM, Vovnovan I, Lasala JP, Sarsenbaeva AS, Fernandez-Salazar L, Molina-Infante J, Jurecic NB, Areia M, Gasbarrini A, Kupčinskis J, Bordin D, Marcos-Pinto R, Lerang F, Leja M, Buzas GM, Niv Y, Rokkas T, Phull P, Smith S, Shvets O, Venerito M, Milivojevic V, Simsek I, Lamy V, Bytzer P, Boyanova L, Kunovský L, Beglinger C, Douberis M, Marlicz W, Goldis A, Tonkić A, Capelle L, Puig I, Megraud F, Morain CO, Gisbert JP; Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). *European Registry on Helicobacter pylori Management Hp-EuReg Investigators. Clin Gastroenterol Hepatol*. 2022 Oct;20(10):2243-2257. doi:10.1016/j.cgh.2021.12.025. Epub 2021 Dec 23. PMID: 34954341 **(I.F. 5.4)**
298. Nyssen Olga P., Moreira Leticia, García-Morales Natalia, Cano-Català Anna, Puig Ignasi, Mégraud Francis, O'Morain Colm, Gisbert Javier P. European Registry on Helicobacter pylori Management (Hp-EuReg):
Most relevant results for clinical practice
Frontiers in Gastroenterology 1,2022 DOI=10.3388.5/fgstr.2022.965982 **(IF 5.5)**
299. Fernández-Salazar L, Campillo A, Rodrigo L, Pérez-Aisa Á, González-Santiago JM, Segarra Ortega X, Denkovski M, Brglez Jurecic N, Bujanda L, Gómez Rodríguez BJ, Ortuño J, Georgopoulos S, Jonaitis L, Puig I, Nyssen OP, Megraud F, O'Morain C, Gisbert JP.

Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacter pylori Infection (Hp-EuReg). *J Clin Med.* 2022 Jun 20;11(12):3544. doi: 10.3390/jcm11123544. PMID: 35743627 **(I.F. 5.0)**

300. Nyssen OP, Vaira D, Saracino IM, Fiorini G, Caldas M, Bujanda L, Pellicano R, Keco-Huerta A, Pabón-Carrasco M, Oblitas Susanibar E, Di Leo A, Losurdo G, Pérez-Aísa Á, Gasbarrini A, Boltin D, Smith S, Phull P, Rokkas T, Lamarque D, Cano-Català A, Puig I, Mégraud F, O'Morain C, Gisbert JP. Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg). *J Clin Med.* 2022 Mar 16;11(6):1658. doi: 10.3390/jcm11061658. PMID: 35329984 Free PMC article. **(I.F. 5.0)**
301. Mortier V, Debaisieux L, Dessilly G, Stoffels K, Vaira D, Vancutsem E, Van Laethem K, Vanroye F, Verhofstede C. Prevalence and Evolution of Transmitted Human Immunodeficiency Virus Drug Resistance in Belgium Between 2013 and 2019. *Open Forum Infect Dis.* 2022 Apr 12;9(7):ofac195. doi: 10.1093/ofid/ofac195. eCollection 2022 Jul. PMID: 35794938 Free PMC article. **(I.F. 4.4)**
302. Van Beckhoven D, Serrien B, Montourcy M, Verhofstede C, Van den Bossche D, Libois A, De Geyter D, Martin T, Van den Eynde S, Vuylsteke B, Darcis G, van Halem K, Florence E, Deblonde J; Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care. Belgian Research on AIDS and HIV Consortium (BREACH). *BMC Infect Dis.* 2022 Dec 3;22(1):901. doi: 10.1186/s12879-022-07879-1. PMID: 36463126 Free PMC article. **(I.F. 3.68)**
303. European Registry on Helicobacter pylori management (Hp-EuReg): Room for improvement in the treatment of Helicobacter pylori infection: lessons from the European Registry on H.pylori management (Hp-EuReg). *The Journal of Clinical Gastroenterology* 2022 Feb 1;56(2):e98-e108 **(I.F. 2.7) Q2**
304. Nyssen OP, **Vaira D**, Tepes B, Kupcinkas L, Bordin D, Pérez-Aísa Á, Gasbarrini A, Castro-Fernández M, Bujanda L, Garre A, Lucendo A, Vologzhanina L, Jurecic NB, Rodrigo-Sáez L, Huguet JM, Voynovan I, Perez-Lasala J, Romero PM, Vujasinovic M, Abdulkhakov R, Barrio J, Fernandez-Salazar L, Mégraud F, O'Morain C, Gisbert JP; Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg). *Hp-EuReg Investigators. J Clin Gastroenterol.* 2022 Feb 1;56(2):e98-e108. doi: 10.1097/MCG.0000000000001482. PMID: 33405435 **(I.F. 2.7)**
305. De Francesco V., Zullo A., Manta R., Satriano A., Fiorini G., Pavoni M., Saracino I.M., Giostra F., Monti G, **Vaira D**. Culture-based antibiotic susceptibility testing for H.pylori infection: an update. *Ann Gastroenterol.* 2022 Mar-Apr; 35(2): 127–134. Published online 2022 Feb 14. doi: 10.20524/aog.2022.0688.5 **(I.F. 2.2)**
306. Francesco V, Zullo A, Manta R, Satriano A, Fiorini G, Pavoni M, Saracino IM, Giostra F, Monti G, Vaira D. Culture-based antibiotic susceptibility testing for Helicobacter pylori infection: a systematic review. *Ann Gastroenterol.* 2022 Mar-Apr;35(2):127-134. doi: 10.20524/aog.2022.0688.5. Epub 2022 Feb 14. PMID: 35479595 Free PMC article. **(I.F. 2.2)**
307. De Francesco V., Zullo A., Manta R., Pavoni M., Saracino I.M., Fiorini G., Giosra F., monti G., Vaira D. First line therapies for Helicobacter pylori infection in Italy: a pooled-data analysis. *Acta Gastroenterol Belg.* 2022 Apr-Jun;85(2):295-299. doi: 10.51821/85.2.9680. **(I.F. 1.3)**
308. De Francesco V, Zullo A, Manta R, Pavoni M, Saracino IM, Fiorini G, Giostra F, Monti G, Vaira D. First-line therapies for H. pylori infection in Italy: a pooled-data analysis. *Acta Gastroenterol Belg.* 2022 Apr-Jun;85(2):295-299. doi: 10.51821/85.2.9680. PMID: 35709773 Free article. **(I.F. 1.3)**

2023

309. Gatta L, Zullo A, **Vaira D**.

Helicobacter pylori eradication and Aspirin: a puzzle yet to be solved.
The Lancet 2023 i2023 Apr 15;401(10384):1265-1266.
doi: 10.1016/S0140-6736(23)00279-9. (I.F. 88.5).

310. Luigi Gatta, Giulia Fiorini, Ilaria Maria Saracino, Matteo Pavoni, Marco Romano, Antonietta Gerarda Gravina, Lucia Granata, Rinaldo Pellicano, Antonio Gasbarrini, Alfredo Di Leo, Giuseppe Losurdo, Francesco Franceschi, Gerardo Nardone, Alba Rocco, Maria Pina Dore, Fabio Farinati, Matteo Ghisa, Ignasi Puig, Olga P. Nyssen 12, Francis Mégraud¹³, Colm O'Morain, Fabrizio Giostra, Giorgio Monti, Massimo Bellini, John Holton, Claudio Borghi, **Dino Vaira**, and Javier P. Gisbert on behalf of the Hp-EuReg investigators. European Registry on Helicobacter pylori Management (Hp-EuReg): Effectiveness of First and Second-Line Treatment in Italy, United European Gastroenterology Journal 2023;11: 103-113. (I.F. 6.9)
311. García-Morales N, Pérez-Aísa Á, Fiorini G, Tepes B, Castro-Fernández M, Lucendo A, Voynovan I, Bujanda L, Garre A, Rodrigo L, Martínez Domínguez SJ, Denkovski M, Huguet Malavés JM, Jonaitis L, Bumane R, Zaytsev O, Mata Romero P, Barrio J, Fernández-Salazar L, Sarsenbaeva AS, Ortiz Polo I, Alekseenko S, Saracino IM, **Vaira D**, Keco-Huerga A, Bordin D, Gasbarrini A, Lerang F, Rokkas T, Kupčinskis J, Leja M, Babayeva G, Marcos Pinto R, Tonkić A, Smith S, Phull P, Buzas GM, Simsek H, Boltin D, Gridnyev O, Venerito M, Milivojevic V, Torà N, Cano-Català A, Moreira L, Nyssen OP, Mégraud F, O'Morain C, Gisbert JP, Puig I, On Behalf Of Hp-EuReg Investigators. Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management. J Clin Med. 2023 Jun 28;12(13):4363. doi: 10.3390/jcm12134363. PMID: 3. (I.F. 5.0)
312. Giulia FIORINI, Ilaria Maria SARACINO, Matteo PAVONI, Bruno NIPOTE, Raffaele COLUCCI, Pietro CAPONE, Angela SANNINO, Fabrizio FORTE, Emiliano DE VERGORI, Mario BRANCACCIO, Maurizio CESAREO, Giovanni CASELLA, Gaetano MORREALE, Leonilde BONFRATE, Piero PORTINCASA, Massimo VINCENZI, Carmelo COTTONE, VITTORIO ORMANDO, Natale SCALISE, Paulin Francis LAWSON, Osvaldo BURATTINI, Amedeo MONTALE, Francesco LUZZA, Mauro ROSSI, Riccardo VANNI, Rosamaria BOZZI, Giuseppina VINCOLI, Nicoletta STEFANI, Claudio BORGHI, **Dino VAIRA**. EFFICACY OF A NEW NUTRACEUTICAL FORMULATION: L-TRIPTOFAN, PROBIOTICS, CHARCOAL, CHAMOMILE, MINT AND LICORICE (COLONIR®) IN THE IMPROVEMENT OF GASTROINTESTINAL SYMPTOMS IN SUBJECTS WITH IRRITABLE BOWEL SYNDROME. Minerva Gastroenterology 2023 Mar;69(1):123-127. doi: 10.23736/S2724-5985.22.03282-X (I.F. 1.5)
313. Jonaitis P, Nyssen OP, Saracino IM, Fiorini G, **Vaira D**, Pérez-Aísa Á, Tepes B, Castro-Fernandez M, Pabón-Carrasco M, Keco-Huerga A, Voynovan I, Lucendo AJ, Lanas Á, Martínez-Domínguez SJ, Almajano EA, Rodrigo L, Vologzanina L, Brglez Jurecic N, Denkovski M, Bujanda L, Mahmudov U, Leja M, Lerang F, Babayeva G, Bordin DS, Gasbarrini A, Kupcinskis J, Gridnyev O, Rokkas T, Marcos-Pinto R, Phull PS, Smith SM, Tonkić A, Boltin D, Buzás GM, Šembera Š, Şimşek H, Matysiak-Budnik T, Milivojevic V, Marlicz W, Venerito M, Boyanova L, Doulberis M, Capelle LG, Cano-Català A, Moreira L, Mégraud F, O'Morain C, Gisbert JP, Jonaitis L; Hp-EuReg investigators. Author Correction: Comparison of the management of Helicobacter pylori infection between the older and younger European populations. Sci Rep. 2023 Nov 1;13(1):18821. doi: 10.1038/s41598-023-45888-5. Erratum for: Sci Rep. 2023 Oct 11;13(1):17235. PMID: 37914853; PMCID: PMC10620194. (IF 4.6)
314. Nyssen OP, Pratesi P, Spínola MA, Jonaitis L, Pérez-Aísa Á, Vaira D, Saracino IM, Pavoni M, Fiorini G, Tepes B, Bordin DS, Voynovan I, Lanas Á, Martínez-Domínguez SJ, Alfaro E, Bujanda L, Pabón-Carrasco M, Hernández L, Gasbarrini A, Kupcinskis J, Lerang F, Smith SM, Gridnyev O, Leja M, Rokkas T, Marcos-Pinto R, Meštrović A, Marlicz W, Milivojevic V, Simsek H, Kunovsky L, Papp V, Phull PS, Venerito M, Boyanova L, Boltin D, Niv Y, Matysiak-Budnik T, Doulberis M, Dobru D, Lamy V, Capelle LG, Nikolovska Trpchevska E, Moreira L, Cano-Català A, Parra P, Mégraud F, O'Morain C, Ortega GJ, Gisbert JP, On Behalf Of The Hp-EuReg Investigators. Analysis of Clinical Phenotypes through Machine Learning of First-Line H. pylori Treatment in Europe during the Period 2013-2022: Data from the European Registry on H. pylori Management (Hp-EuReg). Antibiotics (Basel). 2023 Sep

2024

315. Pabón-Carrasco, M., Keco-Huerga, A., Castro-Fernández, M., Saracino, I. M., Fiorini, G., Vaira, D., Pérez-Aísa, Á., Tepes, B., Jonaitis, L., Voynovan, I., Lucendo, A. J., Lanás, Á., Martínez-Domínguez, S. J., Almajano, E. A., Rodrigo, L., Vologzanina, L., Brglez Jurecic, N., Denkovski, M., Bujanda, L., Abdulkhakov, R. A., ... Hp-EuReg Investigators (2024). Role of proton pump inhibitors dosage and duration in *Helicobacter pylori* eradication treatment: Results from the European Registry on H. pylori management. *United European gastroenterology journal*, 12(1), 122–138. <https://doi.org/10.1002/ueg2.12476> (IF 6.9)
316. Pavoni M, Fiorini G, Zullo A, Saracino IM, Gatta L, Manta R, Imbrogno A, Lazzarotto T, Borghi C, **Vaira D**. Effectiveness of high-dose esomeprazole or pantoprazole 10-day sequential therapy empirically prescribed in *Helicobacter pylori*-infected naïve patients: a retrospective study. *J Gastroenterol Hepatol*. 2024 Aug 26. doi: 10.1111/jgh.16731. Epub ahead of print. PMID: 39188083.
317. Giulia Fiorini, Matteo Pavoni, Matteo Fermi, Giulia Molinari, Andrea Imbrogno, Attilio Varicchio, Ignazio La Mantia, Claudio Borghi, Gabriele Molteni, Livio Presutti and **Dino Vaira**. The clinical challenge of dealing with laryngopharyngeal reflux symptoms: a prospective observational study on a new nutraceutical formulation (CHETOGERD®). Submitted to *Minerva Gastroenterology* (formerly: *Minerva Gastroenterologica e Dietologica*).
318. Huguet, J. M., Ferrer-Barceló, L., Suárez, P., Barcelo-Cerda, S., Sempere, J., Saracino, I. M., Fiorini, G., **Vaira, D.**, Pérez-Aísa, Á., Jonaitis, L., Tepes, B., Castro-Fernandez, M., Pabón-Carrasco, M., Keco-Huerga, A., Voynovan, I., Lucendo, A. J., Lanás, Á., Martínez-Domínguez, S. J., Alfaro Almajano, E., Rodrigo, L., ... Hp-EuReg Investigators (2024). Role of compliance in *Helicobacter pylori* eradication treatment: Results of the European Registry on H. pylori management. *United European gastroenterology journal*, 12(6), 691–704. <https://doi.org/10.1002/ueg2.12569>
319. Del Forno, A., Zullo, A., Marmo, C., Marmo, R., Manta, R., De Francesco, V., Fiorini, G., Pavoni, M., & **Vaira, D.** (2024). Diverticulosis, Adenomas, and Cancer in the Colon: A Systematic Review and Meta-Analysis of Endoscopic Studies. *Journal of clinical gastroenterology*, 58(8), 764–768. <https://doi.org/10.1097/MCG.0000000000002046>
320. Huguet, J. M., Ferrer-Barceló, L., Suárez, P., Barcelo-Cerda, S., Sempere, J., Saracino, I. M., Fiorini, G., **Vaira, D.**, Pérez-Aísa, Á., Jonaitis, L., Tepes, B., Castro-Fernandez, M., Pabón-Carrasco, M., Keco-Huerga, A., Voynovan, I., Lucendo, A. J., Lanás, Á., Martínez-Domínguez, S. J., Alfaro Almajano, E., Rodrigo, L., ... Hp-EuReg Investigators (2024). Role of compliance in *Helicobacter pylori* eradication treatment: Results of the European Registry on H. pylori management. *United European gastroenterology journal*, 12(6), 691–704. <https://doi.org/10.1002/ueg2.12569>
321. Olmedo L, Calvet X, Gené E, et al. Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for *Helicobacter pylori* infection between 2013 and 2021: results from the European registry on H. pylori management (Hp-EuReg). *Gut*. 2024;74(1):15-25. Published 2024 Dec 10. doi:10.1136/gutjnl-2024-332804
322. Saracino IM, Pavoni M, Fiorini G, et al. Updating Primary Antibiotic Resistance in *Helicobacter pylori* Strains Isolated in Italy. *J Gastrointest Liver Dis*. 2024;33(4):463-467. Published 2024 Dec 28. doi:10.15403/jgld-5617

2025

323. Casas Deza D, Alcedo J, Lafuente M, et al. Probiotics Prescribed With *Helicobacter pylori* Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the

324. Zamparini F, Buonavoglia A, Pellegrini F, Diakoudi G, Pavoni M, Fiorini G, Sambri V, Spinelli A, Vaira D, Gandolfi MG, Prati C. Comparative Evaluation of Tongue and Periodontal Pocket Microbiome in Relation to Helicobacter pylori Gastric Disease: 16S rRNA Gene Sequencing Analysis. *Antibiotics (Basel)*. 2025 Aug 6;14(8):804. doi: 10.3390/antibiotics14080804. PMID: 40867998; PMCID: PMC12382620. (IF 5.2)
324. Giulia FIORINI, Massimo RUGGE, Nimish VAKIL, Antonietta D'ERRICO, Matteo PAVONI, Stefano GUZZINATI, Angelo ZULLO, Luigi GATTA, Gabriella MASSARENTI, Beatrice ROSA, Cristina MARCHESANI, Giulia COLLATUZZO, Cinzia PAPADIA, Giovanni BARBARA, Claudio BORGHI, and **Dino VAIRA**. Test-and-treat or test-treat and scope: endoscopy & gastric histology findings in 2,171 consecutive dyspeptic patients. Submitted to *GUT* (IF 31.8)
325. Di Ciaula A, Khalil M, Fiorini G, **Vaira D**, Portincasa P. Why internists should care about Helicobacter pylori: recapitulating gastric cancer prevention. *Intern Emerg Med*. 2025 Oct;20(7):1999-2004. doi: 10.1007/s11739-025-04104-0. Epub 2025 Aug 31. PMID: 40886213. (IF 3.8)
326. Collatuzzo G, Fiorini G, Renieri T, Pavoni M, Boccia S, D'Errico A, **Vaira D**, Boffetta P. Understanding the epidemiology of gastric cancer: a review and case-only analysis from Italy. *Eur J Gastroenterol Hepatol*. 2025 Nov 1;37(11):1249-1259. doi: 10.1097/MEG.0000000000003064. Epub 2025 Aug 29. PMID: 40929649. (IF 1.8)

2026

327. Pavoni M, Tartagni M, Correale R, Gatta L, Fiorini G, Racca D, Zullo A, Arlotti L, Massarenti G, Rosa B, Marchesani C, Collatuzzo G, Manta R, Imbrogno A, Borghi C, **Vaira D**. Accuracy of a new innovative column-free miniaturized gas-mass spectrometer compared with a classic gas-mass spectrometer to diagnose and monitor Helicobacter pylori infection: a prospective single blind study. *Eur J Gastroenterol Hepatol*. 2026 Mar 1;38(3):321-326. doi: 10.1097/MEG.0000000000003088.5. Epub 2026 Jan 28. PMID: 41757610; PMCID: PMC12854363. (IF 1.8)
328. Fiorini G, Gatta L, Pavoni M, Oreste G, Zoppetti G, Massarenti G, Rosa B, Marchesani C, Arlotti L, Collatuzzo G, Manta R, Potena L, Cicero A, Fogacci F, Borghi C, Barbara G, Vaira D. A pre-market, two-stages interventional clinical investigation to evaluate the safety and the performance of Fibroin Syrup in reducing the gastroesophageal reflux symptomatology in non-erosive reflux disease (NERD) patients. *World Journal of Gastroenterology, Hepatology and Endoscopy*. Accepted for publication in 2026. (I.F. 5.4)
329. Fiorini G, Gatta L, Pavoni M, Massarenti G, Rosa B, Marchesani C, Collatuzzo G, Manta R, Potena L, Varricchio A, Cicero A, Fogacci F, Borghi C, Barbara G, Vaira D. Effectiveness of a multicomponent formulation: a prospective observational study in patients with gastroesophageal reflux symptoms. *Pharmaceuticals*. Accepted for publication in 2026. (IF 4.8)
330. Pavoni M, Fiorini G, Saracino IM, Gatta L, Manta R, Holton J, Figura N, Massarenti G, Leo C, Rosa B, Marchesani C, De Razza S, Vaira D. From laboratory to real clinical practice: a multidisciplinary approach towards the next probiotics. *Antibiotics*. Accepted for publication in 2026. (IF 4.6)
331. Fiorini G, Pavoni M, Gatta L, Vakil N, Osborn J, Holton J, Figura N, Saracino IM, Massarenti G, Rosa B, Marchesani C, Lazzarotto T, Cremon C, Marasco G, Barbara G, Papadia C, Borghi C, Vaira D. From bench to bedside: a 10-year translational journey to develop antibiotics-tolerant probiotics to reduce adverse events during Helicobacter pylori eradication treatment, testing their efficacy in a randomised double-blind placebo-controlled trial. *United European Gastroenterol J*. Submitted in 2026.

MONOGRAFIE INTERNAZIONALI

1. *Helicobacter pylori*: what it is, what provokes it, how to recognise and combat it.
Edited by Eurospital. Authors: Figura N, Bayeli P F, Crabtree J E, De Giacomo C, Danielli E, **Vaira D**, 1993.
2. Gastroduodenal pathology and *Helicobacter pylori*.
Report of the VII Workshop on gastroduodenal pathology and *Helicobacter pylori*.
Houston-Texas.
Edited by Well Medical: Authors: P. Malfertheiner, **Vaira D**, 1995.
3. *Helicobacter pylori* infection: basic principles and clinical practice.
Helicobacter pylori infection in childhood.
Edited by Human Science & Technology Press: Authors: Talley NJ, Blaser MJ, Taylor DE, Chua ASB, Axon ATR, Forman D, Stolte M, Blecker U, Keane CT, O'Morain C, Mitchell HM, Buckley M, Tytgat GNJ, Huny RH, **Vaira D**, Oderda G, Lee A, Megraud F, Graham DY 1997.
4. Proceedings of the III Educational Training Workshop in *Helicobacter pylori*.
Edited by Miglioli M, Genta RM, **Vaira D**, Stanghellini V, Corinaldesi R..
1997 *Helicobacter*.
5. Proceedings of the IV Educational Training Workshop in *Helicobacter pylori*.
Edited by Axon ATR, GNJ Tytgat, Miglioli M, Stanghellini V, **Vaira D**, Genta RM, Corinaldesi R.
1998 *Gut*; vol 43; Suppl. No. 1.
6. *Helicobacter pylori* therapy: advances and commercial opportunities.
Edited by Holton J, **Vaira D**, Menegatti M, Miglioli M. 1998 Mosby-Wolfe.
7. Proceedings of the V Educational Training Workshop in *Helicobacter pylori*.
Edited by Axon ATR, GNJ Tytgat, Miglioli M, Stanghellini V, **Vaira D**, Genta RM, Corinaldesi R.
1999 *Gut*; vol 45; Suppl. No. 1.
8. Proceedings of the VI Educational Training Workshop in *Helicobacter pylori*.
Edited by Axon ATR, GNJ Tytgat, Corinaldesi R, **Vaira D**, Stanghellini V, Miglioli M.
Alimentary Pharmacology and Therapeutics, 2000
9. Proceedings of the VII Educational Training Workshop in *Helicobacter pylori*.
Edited by Axon ATR, GNJ Tytgat, Corinaldesi R, **Vaira D**, Stanghellini V, Miglioli M.
Alimentary Pharmacology and Therapeutics, 2001, vol. 15, Suppl.1.
10. Proceedings of the VIII Educational Training Workshop in *Helicobacter pylori*.
Edited by Axon ATR, Corinaldesi R, Miglioli M. Campirei M, Gionchetti P, Stanghellini V, **Vaira D**,
11. *Alimentary Pharmacology and Therapeutics*, 2002, vol. 16; Suppl. 4.
Holton J, **Vaira D**.

Gastric *Helicobacters*

Laboratory Diagnosis of Bacterial Infections.


Edited by N. Cimolai pg 605-634

12. Proceedings of the IX Educational Training Workshop in Helicobacter pylori.
Edited by O'Morain CA, Corinaldesi R, Miglioli M, Campirei M, Bolondi L,
Gionchetti P, Stanghellini V, Gaiani S, **Vaira D**,
Alimentary Pharmacology and Therapeutics, 2003, vol. 17; Suppl. 2.

13. HELICOBACTER PYLORI: An Atlas of Investigation and Management.
Holton J, Figura N, **Vaira B**.
Clinical Publishing, Oxford 2012.

In Fede,

Bologna li, 11/05/2026

A handwritten signature in dark ink, appearing to read "Vaira Berardinelli". The signature is written in a cursive style with a large initial 'V'.